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The minimization of blood loss represents a significant clinical need in the arena of 
surgery, trauma, and emergency response medicine. Fibrinogen is our body’s native 
polymer system activated in response to tissue and vasculature injury, and forms the 
foundation of the most widely employed surgical sealant and hemostatic agent. Non-
covalent knob:hole interactions are central to the assembly of fibrin that leads to network 
and clot formation. This project exploits these affinity interactions as a strategy to direct 
fibrin polymerization dynamics and network structure.  
Short peptides modeled after fibrin knob sequences have been shown to alter fibrin 
matrix structure by competing with native fibrin knobs for binding to the available holes 
on fibrinogen and fibrin. The fusion of such knob peptides to a non-native component 
should facilitate binding of the fused component to fibrinogen/fibrin, and may permit the 
concomitant modification of the fibrin matrix. We examined this hypothesis in a three-
step approach involving (a) analyzing the ability of tetrapeptide knob sequences to confer 
fibrin(ogen) affinity on a non-fibrin protein, (b) investigating the effect of knob display 
architecture on fibrin(ogen) structure, and (c) designing a temperature-responsive knob-
displaying construct to modulate fibrin(ogen) affinity at different temperature regimes, 
thus altering fibrin(ogen) structure. 
We demonstrate that fibrin network structure may be modulated using multivalent knob-
displaying structures. Further optimization of the temperature-responsive knob-display 
system proposed should facilitate the development of a temperature-triggered 






 Uncontrolled hemorrhage has consistently been the leading cause of death due to 
military trauma [1] and ranks second, after central nervous system injuries, in civilian 
trauma deaths [2]. Severe blood loss also poses a major challenge in cardiovascular and 
orthopedic surgical procedures, often necessitating the use of limited resources such as 
human blood products, or expensive hemostatic agents such as recombinant activated 
clotting factor VII (rFVIIa; NovoSeven®) [3, 4]. With the tightening of hospital budgets, 
topical hemostats, on top of cauterization and ligature techniques, are now increasingly 
important tools in surgical practice [5, 6]. Fibrin sealants are particularly prominent as the 
only material approved by the Food and Drug Administration (FDA) for multiple 
indications as hemostat, adhesive, and sealant [7].  
 Fibrin forms the foundation of our body’s native hemostatic system and is 
activated as the final step of the coagulation cascade in response to tissue and vasculature 
injury. In the surgical setting, fibrin sealants are administered as two-component systems 
comprising the precursor fibrinogen, and the activating enzyme, thrombin [8, 9]. Due to 
the high concentrations of fibrinogen (80-120 mg/mL) and thrombin (300-600 NIH-
U/mL) used to ensure rapid clotting, there is a high chance of clogging the delivery 
system at the point of deployment. This limits the utility of this inherently biocompatible 
material in procedures where surgical timing and precision is paramount. In response, we 
seek to develop a fibrin mixture that only forms a cohesive matrix upon warming at the 
site of application. By shifting the clotting trigger from enzyme to temperature, we expect 
to improve the handling of fibrin sealants, particularly for minimally invasive surgeries 
where the product has to be delivered via long narrow catheters to the point of 
application. 
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 To facilitate the develop of this temperature-triggered in situ polymerizing fibrin 
mixture, this work examines the utility of affinity interactions, specifically fibrin 
knob:hole interactions, in the manipulation of fibrin matrix properties. Fibrin network 
formation from fibrinogen is mediated by both thrombin and clotting factor XIII (FXIII), 
the latter of which is commonly co-purified with plasma-derived fibrinogen. In particular, 
the non-covalent knob:hole affinity interactions effected by thrombin cleavage are 
directly responsible for the rapid assembly of fibrin monomers into protofibrils and 
fibrils, which feeds into activated FXIII (FXIIIa) crosslinking activity by the 
juxtaposition of its substrate sites. Knob:hole interactions therefore play a crucial role in 
directing fibrin network structure and consequently, matrix properties. We hypothesize 
that the perturbation of these interactions through the addition of knob-displaying non-
fibrin entities will modulate the mechanical properties of the resulting fibrin matrix. 
 The addition of synthetic peptide knob mimics (glycine-proline-arginine-proline; 
GPRP) has been shown to arrest fibrin assembly at high dosages [10]. Similarly, we 
expect the addition of knob-displaying conjugates to alter the native 1:1 knob-to-hole 
ratio in polymerizing fibrin mixtures, hence impact matrix structure and stability. Since 
knob:hole interactions are central to fibril assembly, we anticipate that knob display 
configuration will also have an effect on fibrin(ogen) assembly dynamics and resulting 
network structure. In addition, non-covalent affinity interactions are inherently sensitive 
to the surrounding conditions and in combination with a stimuli-responsive element, 
should facilitate the design of temperature-responsive conjugates that differentially 
perturb fibrin matrix structure at different temperature regimes. 
 This thesis examines our starting hypothesis in three stages. First, we demonstrate 
that the presentation of a short tetrapeptide knob sequence is sufficient to confer 
fibrinogen and fibrin affinity on a non-fibrin protein. Here, we introduced GPRP on the 
N-terminus of the model protein, fibronectin type III domains 9-10 (FNIII9-10) through 
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recombinant protein engineering. The expressed protein, GPRP-FNIII9-10, was shown to 
bind stably and specifically to fibrinogen and fibrin (detailed in Chapter 3). 
 Second, we demonstrate that knob-display configuration affects fibrinogen and 
fibrin structure. Here, we conjugated GPRP to the terminal ends of 2-arm and 4-arm 
polyethylene glycol (PEG) structures via sulfhydryl-maleimide chemistry. These multi-
arm conjugates, GPRP2-PEG and GPRP4-PEG, formed networks with fibrinogen and 
altered fibrin assembly dynamics (detailed in Chapter 4). The structure of the resulting 
network was shown to be dependent on the conjugate size. 
 Finally, we developed a thermo-responsive knob-displaying mixed micelle system 
that alters fibrin structure in a temperature-dependent manner. Here, we expressed GPRP 
on the N-terminus of diblock temperature-responsive elastin-like polypeptides (ELP) 
using recombinant protein engineering. The expressed proteins, GPRP-ELPB-ELPA and 
GPSP-ELPC-ELPA, formed mixed micelles exhibiting variable avidities for fibrinogen at 
different temperature regimes (detailed in Chapter 5).  
 In summary, this work demonstrates our ability to alter the distribution of 
physical (non-covalent) and chemical  (covalent) crosslinks within fibrin networks 
through the addition of knob-displaying constructs, thereby altering clot structure. This 
strategy provides an orthogonal means of manipulating fibrin network structure and 
mechanical properties, driving matrix formation from being a purely enzyme-triggered 
process towards one that is stimulus-responsive. 





Many strategies in tissue engineering and regenerative medicine focus on the use 
of provisional matrices to harness the healing resources of the body for tissue repair. By 
providing a three-dimensional scaffold with the appropriate spatial and temporal cues, the 
invading or encapsulated cells can populate and remodel the matrix to match the 
surrounding milieu, creating a seamless transition between host and replacement tissue 
[11-13].  
The fibrin networks that form spontaneously at injury sites in vivo are the 
foundation of our body’s native provisional matrix. Following external application of 
fibrin sealants during surgeries, the matrices formed are similarly resolved within days to 
weeks and appear to promote angiogenesis and local tissue growth and repair [9]. To 
preserve these favorable properties, we seek to modify the fibrin matrices using 
components that have also been shown to have favorable biocompatible and/or 
biodegradable properties. 
This chapter reviews the mechanisms behind fibrin matrix formation, particularly 
the role of knob:hole interactions in fibrin assembly and FXIIIa crosslinks in network 
stabilization. Methods of altering fibrin network structure in the interest of applying these 
scaffolds in tissue engineering and regenerative medicine applications are also covered. A 
review of PEG and ELP-based materials as potential scaffolds is also included.   
2.1.  Fibrinogen and Fibrin 
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Fibrinogen circulates at ~3 mg/mL in the blood as a 340 kDa glycoprotein 
comprising a symmetrical pair of three protein chains - Aα, Bβ and γ (Figure 1A). 
Fibrin(ogen) features numerous binding sites for pro-coagulant proteins (thrombin, factor 
XIII), pro-fibrinolytic proteins (plasminogen, tissue plasminogen activator), anti-
fibrinolytic proteins (plasminogen activator inhibitor), growth factors (fibroblast growth 
factor-2, vascular endothelial growth factor, platelet derived growth factor), extra-cellular 
matrix components (fibronectin, heparin), and cell receptors (integrins, cadherins) [14, 
15]. A number of these components are co-purified with plasma-derived fibrinogen in 
commercial fibrin sealants and support the formation and remodeling of the fibrin matrix, 
thereby aiding the smooth transition of the provisional scaffold into the local tissue 
structure as the wound heals. Fibrin therefore has many favorable biological properties as 




Figure 1. Fibrinogen and fibrin polymerization schematic. (A) Illustration of the basic fibrinogen 
structure depicting the Aα  chain in green, Bβ  chain in blue, γ  chain in red. The length of the αC tail 
is variable depending on the species and isoform. (B) Steps involved in fibrin polymerization. Note: 







2.1.1. Fibrin Network Formation 
Fibrin network formation, or fibrin polymerization, from its precursor fibrinogen 
is initiated upon activation of the clotting enzymes, prothrombin and FXIII. In vivo, 
prothrombin is proteolytically cleaved and activated by activated clotting factor X in the 
first common step of the intrinsic (or contact factor) and extrinsic (or tissue factor) 
activation pathways of the coagulation cascade.  
The activated serine protease, thrombin, catalyzes the removal of fibrinopeptides 
(FpA, FpB) from the N-terminal regions of the Aα and Bβ chains of fibrinogen, exposing 
short peptide sequences known as knob ‘A’ and knob ‘B’ that bind to hole ‘a’ and hole 
‘b’ in the C-termini of neighboring fibrin(ogen) molecules (Figure 1B). The cleaved 
fibrin monomers without FpA and FpB are denoted (αβγ)2, in contrast with precursor 
fibrinogen, (AαBβγ)2. 
The central location of the knobs in region E, contrasting with the distal location 
of the holes in region D, results in the formation of half-staggered two-stranded 
protofibrils that associate to form the fibrin network. Thrombin also activates the 
transglutaminase, clotting factor XIII (FXIII). Activated FXIII (FXIIIa) initiates the 
formation of γ-glutamyl-ε-lysyl amide bonds between substrate sites on the γ and α 
chains of adjacent fibrin(ogen) molecules.  
The timescale for the chemical crosslinking of fibrin is typically orders of 
magnitude (minutes to hours) larger than the assembly of monomers initiated by the 
release of fibrinopeptides (seconds to minutes). Fibrin network structure is therefore 
largely dictated by the release kinetics of the fibrinopeptides and concomitant exposure of 
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knobs, whose knob:hole binding kinetics is in turn dependent on factors such as enzyme, 
substrate and ion concentration.  
2.1.2.  Knob:Hole Interactions 
Four types of knob:hole interactions may be postulated, namely, A:a, A:b, B:a, 
B:b. Early studies employing classical binding assays between fibrinogen and synthetic 
peptide sequences mimicking knob ‘A’ (glycine-proline-arginine-proline; GPRP) and 
knob ‘B’ (glycine-histidine-arginine-proline; GHRP) suggested that these sequences had 
separate and distinct binding sites, although some cross-reactivity was observed [10]. X-
ray crystallographic structures of fibrinogen fragment D together with knob ‘A’ and ‘B’ 
mimics confirmed the notion that knob ‘A’ bound to hole ‘a’ located in the C-termini of 
the γ chains while knob ‘B’ bound to the homologous hole ‘b’ of the β chains [18]. 
Laser tweezer (or gradient optical trap) experiments using fibrinogen and knob A-
displaying or knob A- and B-displaying fibrin fragments found that A:a interactions were 
the dominant interactions, with measured individual binding strengths of  125-130 pN 
and a low zero-force off-rate of 10-4 s-1 [19]. Abolishing the A:a interactions through the 
use of variant forms of fibrinogen, B:b binding strength was found to be ~15-20 pN [20]. 
Complementary experiments using surface plasmon resonance (SPR) found that the 
equilibrium binding constants between fibrinogen and knobs ‘A’ or both knobs ‘A’ and 
‘B’ were statistically similar (5.8 ± 1.1 µM vs 3.7 ± 0.7 µM, p = 0.14), suggesting that 
A:a interactions are much stronger than B:b even though both participate in fibrinogen 
binding [21]. 
In general, thrombin-mediated FpA release, forming type I fibrin or (αBβγ)2 
comprising A:a interactions, occurs at a faster rate than FpB release, forming type II 
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fibrin or (αβγ)2 comprising both A:a and B:b interactions [22-24]. In addition, certain 
snake-derived thrombin-like serine proteases preferentially cleave either FpA (e.g. 
batroxobin, ancrod) or FpB (e.g. venzyme). Notably, batroxobin-catalyzed fibrin clots are 
largely similar to thrombin-catalyzed clots, while venzyme-catalyzed clots are only stable 
below physiological temperatures [25, 26], suggesting that B:b interactions alone are not 
sufficient for the stable assembly of fibrin monomers. From a clinical perspective, the 
majority of human fibrinogen variants identified (i.e. due to dysfibrinogenemia, 
hypofibrinogenemia, or afibrinogenemia) can be traced back to amino acid substitutions 
near the knob ‘A’ and hole ‘a’, again suggesting that A:a interactions are key to stable 
fibrin assembly [27]. 
In conclusion, extensive research recognizes knob A mimics, in particular GPRP, 
as the strongest fibrin(ogen) binding tetrapeptude sequence. GPRP-conjugated affinity 
columns have been used for the purification of fibrinogen and the hole-containing 
fragment D [28]. GPRP-related peptides have also been postulated as potential 
anticoagulants, given their ability to disrupt fibrin assembly [10, 29, 30]. Similarly, this 
work focuses on the use of GPRP-conjugated constructs for the perturbation of fibrin 
polymerization dynamics. 
2.1.3.  Fibrin Crosslinks 
FXIII, also known as the fibrin stabilizing factor, crosslinks the α and γ chains of 
fibrin(ogen), producing a mechanically stronger, more rigid and more elastic clot with 
increased resistance to fibrinolysis (reviewed in [31, 32]). FXIII circulates in the plasma 
at a concentration of 14-28 µg/mL, mainly in association with fibrinogen due to its large 
binding constant (KD ~ 10-8 M) for the molecule [33]. As such, FXIII is co-purified with 
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plasma-derived fibrinogen in most commercial fibrin sealants, contributing to fibrin 
crosslinking and clot strength following application [34].  
FXIII is activated by proteolytic cleavage of thrombin, releasing the activation 
peptide and exposing the active-site cysteine. Typically, γ-γ dimers are formed within 
seconds of thrombin-activated polymerization, while higher order α-α and α-γ hybrid 
oligomers are formed more slowly as the clot matures [35, 36]. Crosslinking of non-fibrin 
proteins such as α2 plasmin inhibitor and fibronectin to lysine residues on the α chain, 
while physiologically important, also occurs at a slower rate compared to γ-γ 
dimerization [37]. 
The higher crosslinking rate of fibrin as compared to fibrinogen is well 
established and commonly attributed to the favorable alignment of the substrate sites in 
the assembled fibrin fibril [38, 39]. Addition of a large excess of GPRP to polymerizing 
fibrin mixtures (thus disrupting fibrin assembly as demonstrated by [10]) slowed γ-γ 
dimerization by over 30-fold, but had no significant effect on fibrinogen mixtures [40].  
Conversely, γ-γ crosslinking of fibrinogen or fragment D may be enhanced by the 
presence of thrombin-activated fragment E (containing knobs ‘A’) that forms a tether 
between the C-terminal γ modules (containing holes ‘a’) of fragment D [41]. The addition 
of GPRP reduced the crosslinking rate to basal levels, suggesting that fragment E acts as 
an organizing template to spatially orient fibrin(ogen) region D for favorable reaction 
with FXIIIa [41]. Similarly, a two-headed GPRP linker mimicking the tethering function 
of fragment E promoted γ-γ dimerization [42]. Large excess of the linker, where we 
would expect nonproductive binding (i.e. the two-headed GPRP linker essentially 
functions like monovalent GPRP), again reduced crosslinking to basal levels. Notably, 
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the ratio of linker to fragment D to achieve maximum % crosslinking was close to 1:1 
[42], as we would expect from a 1:1 knob:hole interaction. 
In short, FXIIIa crosslinking activity, particularly γ-γ dimerization, is strongly 
associated with fibrin assembly mediated by knob:hole interaction. By extension, we 
expect that alterations in fibrin network structure arising from fibrin assembly should 
have an impact on the crosslinking kinetics, thereby altering clot rheology.  
2.1.4.  Fibrin Network Structure and Clot Stiffness 
Differences in clot stiffness can have significant physiological implications, in 
that highly rigid clots may be prone to thrombosis, while fragile clots may lead to 
premature lysis and re-opening of the wound [43]. From our understanding of fibrin clot 
formation, we expect clot rheology to be dependent on both the assembled network 
structure arising from non-covalent knob:hole interactions, as well as covalent crosslinks 
introduced by FXIIIa. 
Fibrin network structure is typically modified by varying clotting conditions such 
as fibrinogen and thrombin concentration, buffer ionic strength (typically sodium 
chloride, NaCl [44]), calcium ion concentration (typically calcium chloride, CaCl2), pH, 
and the use of alternative thrombin-like clotting enzymes (e.g. ancrod, batroxobin) [25, 
45, 46]. Translucent clots formed at high thrombin or high NaCl concentration are 
commonly interpreted to be thin, highly-branched networks. Opaque clots are formed at 
low NaCl or high calcium concentration, conditions that apparently favor lateral 
aggregation of the fibrin protofibrils, giving rise to thicker bundles that scatter more light 
[46]. 
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The relationship between fibrin polymerization kinetics and the resulting network 
structure was first formally established by Weisel and Nagaswami using a kinetic model 
[46]. In general, large fiber diameters and lengths were associated with minimal 
branching and the converse was also true. Following up, the group showed that greater 
branching led to increased clot rigidity but that the reduced fiber diameters also softened 
the network [47]. Thus, clot rigidity was maximal at an intermediate thrombin 
concentration of 0.25 NIHU/mL and at 0.15 mM CaCl2. Interestingly, the authors also 
found that γ monomer depletion (due to γ chain crosslinking) was completed within 2 
hours at 0.2 mM CaCl2 while a progressive depletion of α monomers (due to α chain 
crosslinking) occurred from 0.2 to 20 mM CaCl2 [47]. 
While it is clear that FXIIIa-catalyzed crosslinking increases clot stiffness, it is 
less clear how each type of crosslink (γ-γ dimers, γn multimers, αn polymers, αm-γn 
hybrids) contributes to clot rigidity. In the absence of crosslinks, fibrin clots have been 
shown to experience slight creep and irrecoverable deformation [48]. Diffusion of GPRP 
(thus disrupting fibril assembly) into such clots decreased the shear modulus and 
eventually liquefied the clot [49]. On the other hand, ligated clots displayed almost 
perfect elastic behavior in creep and creep recovery tests [50, 51]. Notably, the structural 
integrity of these clots appeared to be maintained even in the presence of GPRP [49], 
demonstrating the importance of the covalent crosslinks in maintaining clot stability 
independently of fibrin assembly mediated by knob:hole interactions. 
FXIIIa-mediated crosslinking does not affect clot architecture and is not visible 
under electron microscopy [47]. Even though γ-γ dimerization occurs much faster than α 
chain crosslinking, it is thought that αn polymers are the major contributors to clot 
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rigidity [52, 53]. However, caution must be taken in interpreting these early results due to 
the popular use of calcium and EDTA (ethylenediaminetetraacetate) to modulate the 
crosslinking activity of this calcium-sensitive enzyme [52]. As discussed above, calcium 
ion concentration also affects fibrin network structure and clot rigidity. Consequently, 
many recent papers use fibrinogen variants with mutated or deleted FXIIIa crosslinking 
sites to study the effect of crosslinking independently of clot structure. 
Using a patient-derived antibody that inhibit α chain but not γ chain crosslinking, 
Ryan et al. found that the elastic modulus of the clot was reduced by twofold despite 
nearly complete γ-γ crosslinking [54]. Using recombinant fibrinogen without the C-
terminal α chain FXIIIa crosslinking sites (α251 fibrinogen), Collet et al. showed that the 
clots produced were also less stiff and had a higher loss modulus than control clots [55]. 
However, they also found that ligated α251 fibrin clots were stiffer than their unligated 
counterparts, suggesting that γ chain crosslinking also contributes to the mechanical 
stability of clots [55]. Creating a fibrinogen variant with mutated γ chain crosslinking 
sites, Standeven et al. affirmed the contribution of γ-γ dimerization to clot stiffness [56]. 
In particular, γ-γ crosslinking may be a prerequisite for the production of higher-order 
crosslinked species (γn, αn, αm-γn) that maximally enhance network stiffness as the clot 
matures [54, 56]. 
In summary, clot stiffness is a function of both fibrin network structure as well as 
α and γ chain crosslinks, and that both factors are interrelated and interdependent under 
most experimental conditions used in literature. 
2.1.5.  Fibrinolysis 
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In vivo, the events that trigger coagulation also initiate the process of fibrinolysis 
via the activation of plasminogen to form the active serine protease, plasmin. The 
fibrinolytic process itself is modulated via a complex web of biochemical processes 
involving plasminogen activators (tPA, uPA), plasminogen activator inhibitors (PAI-1, 
PAI-2) and fibrinolysis inhibitors (thrombin-activated fibrinolysis inhibitor or TAFI), 
amongst others [57]. 
By varying ionic strength and thrombin concentration, Carr and Alving found that 
fibrinolytic rate increased with fibrin fiber diameter [58]. Here, exogenous tPa was added 
at the point of thrombin addition, or one hour post-clotting as an overlay. Clot dissolution 
was quantified using both turbidimetry and release of 125I-labeled fibrinogen. In contrast, 
Kolev et al. found that fibrinolytic rate decreased with fibrin fiber diameter [59]. Here, 
the authors were interested in modeling the surface degradation rates of clots overlaid 
with plasmin  (and several other proteases) of varying concentrations. While fibrin 
degradation was again monitored with release of 125I-labeled fibrinogen, it should also be 
noted that the range of NaCl used in this work was of a different regime from Carr and 
Alving, which could explain the discrepancy. 
A more recent paper from Weisel’s group investigated the morphological features 
of fibrin formation and dissolution using gold-labeled fibrinogen under a confocal 
microscope [60]. This paper confirmed earlier suggestions that fibrinolysis occurred via 
lateral transection, leading to the progressive disaggregation of the whole fiber structure. 
However, while thinner fibers were digested more quickly, thicker fibers were more 
likely to undergo agglomeration, a process that has been shown to accelerate fibrinolysis 
[60]. In addition, it was discovered recently that the addition of knob B synthetic peptide 
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mimics increased clot turbidity but delayed fibrinolysis [61]. In particular, the authors 
pointed out that turbid clots generated using calcium ions were different from the turbid 
clots formed in the presence of these peptides, in that the latter delays the activation of 
plasminogen by tPA. Hence, the relationship between fiber diameter, or clot turbidity, 
and fibrinolytic rate is hardly straightforward. 
A similar controversy exists with respect to evaluating the contribution of α and γ 
chain crosslinking towards fibrinolytic rates. Due to the complex regulatory mechanisms 
behind plasmin activation, it may well be true that we are unlikely to find any directly 
measurable relationship between fibrinolytic rate and the degree of crosslinking [56, 62]. 
2.2.  Polyethylene glycol 
Synthetic polymers are valued for their ease of synthesis and fabrication, leading 
to their present wide use in sutures and various implant and orthopedic devices. In 
particular, PEG has been used in a wide variety of biomedical applications, as non-
fouling surface coatings [63, 64], as conjugates [65, 66], and as hydrogels or drug 
delivery scaffolds [67].  
2.2.1.  PEGylation 
PEGylation, or the conjugation of PEG to molecules of interest, is an enabling 
technology that is routinely used to improve the pharmacokinetics of therapeutic drugs 
and small proteins (reviewed in [68-70]). PEGylation reduces the immunogenicity of 
molecules by reducing their accessibility to antibodies and proteolytic enzymes through 
steric hindrance imparted by the mobile polymer chains. The hydrophilic PEG chains 
also impart solubility and increase the hydrodynamic radius of the parent molecule, thus 
reducing kidney clearance and increasing the blood circulation time of small proteins or 
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peptides. In general, PEG less than 20 kDa in size is cleared by the kidney, while 
hepatobiliary clearance dominates above 50 kDa [68]. 
Conjugation via the sulfhydryl group of cysteine is one of the most specific 
methods of in vitro protein modification due to the lower abundance of cysteine residues 
as compared to amine-containing lysine residues [69]. Use of this strategy in PEGylation 
has been gaining popularity as genetic engineering and recombinant protein production 
allows for the introduction of deliberately placed cysteine residues for site-directed 
conjugation [71-74]. This is particularly useful when amino groups are involved in 
protein function since amine-mediated conjugation chemistries might inadvertently target 
the active site of the protein, resulting in an inactive conjugate. Notably, sulfhydryl-
maleimide reactions can be carried out efficiently under mild conditions so as to preserve 
protein/peptide function [75]. 
The huge success of commercial PEGylated products (Adagen®, PEG-Intron® , 
Pegasys®, Neulasta®, etc.) has led to the ready availability of low polydispersity (Mw/Mn 
< 1.05) functionalized PEGs with a variety of functional groups and sizes (typically 2 
kDa up to 40 kDa) for various applications in biomedical research.  
2.2.2.  PEG as Ligand Linkers 
Successful commercialization of PEGylated constructs, typically molecules with 
one or more PEG chains attached, has also spurred the development of the reverse 
scenario, namely “multivalent conjugates” involving PEG structures with one or more 
active molecules attached. In its simplest form, this refers to the use of PEG as a flexible 
linker between two ligands, which should especially facilitate the binding of the ligand to 
targets with multiple binding sites [76]. Upon the binding of one of the ligands, the 
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diffusion of its tethered cognate will be constrained within a hemisphere of radius equal 
to the root-mean-square length of the linker, increasing its binding probability, hence 
enhancing the apparent affinity of the conjugate. Thus, the optimal linker length should 
be close to the distance between the ligand binding sites of the target [76]. 
In a comprehensive study on the effect of different PEG architectures on ligand 
binding, Baird et al. studied the effect of monovalent, bivalent, bismonovalent, 
bisbivalent and dendrimer PEG configurations on 2,4-dinitrophenyl (DNP) binding to 
anti-DNP immunoglobulin E (IgE) receptors on RBL mast cells [77]. Here, the authors 
found that there was an optimal linker length for achieving stable nonstimulatory 
intramolecular receptor crosslinking and that bisbivalent ligands were more effective 
inhibitors due to the presence of two DNP groups at each end of the conjugate. In a 
subsequent study modeling the interaction of these conjugates with anti-DNP IgE in 
solution, they again found the presence of an optimal linker length for achieving the 
maximum effective affinity and minimum IC50 [78]. 
In short, PEGylation provides a convenient and reproducible means of generating 
conjugates with different peptide display configurations on an inert backbone structure. 
2.2.3.  PEG Hydrogels 
As a hydrophilic but biologically inert material, PEG may be functionalized and 
crosslinked to form hydrogels as replacement scaffolds for metabolically active soft 
tissues. The macroscopic properties (e.g. compressive modulus, mesh size) of these 
hydrogels may be tuned to the desired parameters by varying crosslinking density, which 
is in turn dependent on monomer and crosslinker structure and the specific 
polymerization conditions [79, 80].  
 17 
PEG-based hydrogels are often used as blank-slate three-dimensional templates 
onto which biological functionalities may be added. Cell adhesion peptides (e.g. arginine-
glycine-aspartate-serine or RGDS) for promoting cell attachment [81] and the 
incorporation proteolytic sensitive peptides sequences [82] are common modifications of 
synthetic PEG hydrogels. 
2.2.4.  PEG-Fibrin Hydrogels 
Blends of natural and synthetic components are often used in the design of 
hydrogels for use in tissue engineering and regenerative medicine in order to fulfill both 
the mechanical and biological requirements of their intended application [83]. Thus, 
several attempts have also been made to blend the favorable mechanical properties of 
PEG with the rich biological properties of fibrinogen/fibrin. 
Fibrinogen is stabilized by 17 interchain and 12 intrachain disulfide bonds [84]. 
By denaturing fibrinogen and reducing the disulfide bonds, then crosslinking the free 
sulfhydryls using PEG-diacrylate, Seliktar’s group has created a variety of PEG-fibrin 
hybrid gels with varying structural characteristics (reviewed in [85]). By varying the 
relative proportions of fibrinogen and PEG, as well as the size of the PEG-diacrylate 
crosslinker used, they were able to achieve a range of elastic modulus from 0.01 to 
several kPa [86]. These gels exhibited a range of degradation rates, resulting in different 
cellular invasion kinetics [87]. 
In a different approach, Suggs’ group used functionalized amine-reactive PEG 
(via benzotriazole carbonate or succinimidyl esters) to PEGylate fibrinogen [88, 89]. 
Since free lysine residues were used in the PEGylation reaction, fibrinogen did not have 
to be denatured or reduced, and can subsequently be crosslinked through the addition of 
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thrombin if the PEGylation ratio is less than 10 [89, 90]. Indeed, a structural investigation 
of Seliktar’s sulfhydryl-targeted PEG-fibrinogen conjugates suggested that while the 
protein secondary structure was preserved, the unfolded polypeptides may not fold back 
into its native conformation and instead assemble to form elongated aggregates [91]. 
2.3.  Elastin-Like Polypeptides 
Elastin-like polypeptides or elastin-mimetic proteins are chemically or 
recombinantly synthesized biopolymers modeled after repeating sequences in the 
mammalian elastin protein [92]. The ability to produce high yields of ELPs with specific 
sequences using standard recombinant protein engineering methods has greatly facilitated 
the development of ELP nanostructures and materials with carefully tuned microscopic 
and macroscopic properties for diverse biomedical and biotechnogical applications [93, 
94].  
2.3.1.  Inverse Phase Transitioning Behavior 
ELPs reported in literature commonly comprise repeats of the pentapeptide 
sequence, VPGXG, where X may be any amino acid. Above a transition temperature, Tt, 
ELPs reversibly self-assemble by hydrophobic association, forming micron-sized 
aggregates that then coalesce to form a dense coacervate [95].  Based on the Urry model, 
the P2G3 dipeptide is responsible for the formation of type II β-turns that are key points in 
the folding/dehydration and unfolding/hydration process, while the guest residue in 
position 4 can be varied to create ELPs with different Tt [96, 97]. Multicanonical 
simulations of pentapeptides with substitutions in position 4 support the idea that the 
hydrophobicity of the guest residue affected conformational transition temperature but 
not secondary structure [98]. 
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The simplest ELPs are designed using aliphatic amino acids (glycine, alanine, 
valine, isoleucine, leucine) as guest residues since these uncharged non-polar residues 
primarily respond to temperature for the thermodynamically driven collapse of the 
hydrated protein chain [99]. Their transition temperatures fall within the experimentally 
accessible range from approximately 5°C for poly(VPGLG) to 55°C for poly(VPGGG) 
[96]. In addition, the Tt of these ELPs were shown to vary linearly with the mole fraction 
of the guest residue within a copolymer, allowing further turning of the Tt if desired. 
Using recombinant protein design and production. Chilkoti’s group has conducted 
extensive studies on the effects of ELP chain length, composition and concentration on 
the thermal transitioning behavior of ELPs containing glycine/alanine/valine as guest 
residues [100, 101].  
The inverse phase transitioning behavior of ELPs has prompted many 
comparisons with the synthetic polymer equivalent, poly(N-isopropylacrylamide) or 
PNIPAM, which has a phase transitioning temperature at approximately 32°C. In 
particular, the cloud points of ELPs exhibit an unusually strong concentration dependence 
[100]. Comparisons with PNIPAM suggest that this may be due to chain stiffness arising 
from the β-turns within the protein chain below its Tt, thus preventing intramolecular 
association and coiling [102, 103]. This is congruent with the observation that the 
concentration dependence of the cloud point decreases with increasing ELP chain length 
and that a critical transition temperature is reached at sufficiently high protein 
concentrations [100]. 
2.3.2. ELPs as Protein Capture Tags 
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The thermally-induced hydrophobic collapse and aggregation of ELPs can be 
utilized as a convenient means of purifying ELPs and ELP-tagged proteins in a process 
known as inverse transition cycling (ITC) [104-106]. In particular, the addition of salt (of 
up to 3 M NaCl) allows the Tt to be modulated over a 50°C range, allowing ITC to be 
carried out isothermally at ambient conditions if desired [103, 105]. ELP-tagged proteins 
are produced with extremely high yields (> 100 mg per liter of culture) and can be stably 
stored frozen in buffer at high concentrations of 100-150 mg/mL without the need for 
protein stabilizers like glycerol [106]. In the case of poorly expressed proteins, free ELPs 
may be added as a co-aggregant to capture and purify the ELP-tagged protein [107].  
The use of ELPs as capture tags was demonstrated by Chilkoti’s group using 
immobilized ELPs on a nanopatterned surface. High salt was used to trigger the capture 
of ELP-tagged proteins on an ELP-conjugated surface, which could then be regenerated 
using a low salt buffer [108]. In a similar vein, Sun et al. developed a one-pot glyco-
affinity precipitation protocol by conjugating carbohydrate ligands to ELPs via the 
glutamic acid residue using carbodiimide chemistry [109]. The glyco-ELP conjugates 
interacted with lectins in solution and co-precipitated with these proteins above Tt.  
2.3.3. ELP hydrogels 
The high biocompatibility of ELPs together with their ease of purification permits 
the use of large quantities of the material in tissue engineering and regenerative medicine. 
As proof of feasibility, Urry et al. demonstrated the successful in vivo application of 
several ELP variants in soft tissue augmentation and generation with the eventual goal of 
developing an injectable periurethral support material for correcting stress urinary 
incontinence [110].  
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While the shear modulus of an ELP solution below Tt is almost three orders of 
magnitude smaller than that of the coacervate above Tt, this can be changed by 
crosslinking the protein chains [111]. Crosslinked ELP hydrogels have been created using 
γ irradiation [112], glutaraldehyde or tris-succinimidyl aminotriacetate or 
tris(hydroxymethyl)phosphino-propionic acid targeting lysine residues [113-115], and 
tissue transglutaminase targeting lysine and glutamine resides [116]. Such crosslinked 
hydrogels are known to contract and expel water above their phase transition temperature 
[112, 114, 115]. 
Alternatively, physical “crosslinks” can be introduced via selective block collapse 
of triblock ELPs. These B-A-B triblock ELPs (where Tt,B < Tt,A) exist as monomers 
below the transition temperature but when heated above the phase transition (Tt,B), the 
flanking hydrophobic B blocks undergo desolvation and associate into micellar 
aggregates that act as virtual crosslinks between the central hydrophilic block [117]. 
Notably, careful control of the liquid phase transitions during hydrogel formation gave 
rise to scaffolds with varying meso- and nano-scale structures, resulting in differences in 
elastic moduli of over three orders of magnitude [118].  
2.3.4.  Self-Assembling ELP Systems 
The ability to precisely control the composition and chain length of ELPs through 
genetic engineering has led to the use of ELP block copolymers for the development of 
various self-assembling systems [119]. In the simplest permutation, the steroid drug 
dexamethosone was passively encapsulated within microparticles of an elastin-like 
polymer, resulting in drug release over a period of up to 35 days [120].  
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In a more complex design, Chilkoti’s group showed that ELP diblocks formed 
stable micellar structures of less than 100 nm in diameter following the thermally-
induced collapse of the block with the lower Tt [121]. Presentation of the integrin-binding 
RGDS ligand on the hydrophilic block resulted in the temperature-triggered enhanced 
binding of the multivalent protein micelle to K562 cells expressing the αvβ3 integrin 
[122]. Diblock proteins with a crosslinkable ELP core (incorporating lysines) have also 
been created, facilitating study of the stabilized micellar structures under ambient 
conditions [123]. 
2.3.5. Short ELPs as Molecular Actuators 
An intriguing area of ELP research capitalizes on chain conformation transition to 
effect a mechanical contraction. The potential for the use of ELPs as free energy 
transducers or molecular motors was first demonstrated by Urry et al. around the mid-
1980s [124]. Given growing interests in the potential use of ELPs as molecular actuators, 
the mechanism behind the conformational transition of model ELP polypeptides has been 
studied by several different groups over the past decade [102, 125-128]. 
After demonstrating that short ELPs exhibit the same temperature-induced 
structural transitions as the longer polymers studied by other groups [128], Reiersen et al. 
substituted the inter-helix turn of protein A with an ELP linker. At high temperatures, the 
linker formed a type I β-turn, aligning the two helices of protein A and increasing binding 
affinity to IgG by 21-fold [129]. Similarly, Megeed et al. substituted the flexible linker 
between the VH and VL domains of the single-chain antibody anti-fluoresceine scFv 
4D5Flu with an ELP linker [130]. Raising the temperature triggered contraction of the 
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linker and separation of VH and VL, disrupting the fluorescein binding site and resulting 
in faster ligand release [130]. 
In the reverse scenario, ligand binding has also been known to affect ELP 
transition characteristics. When the globular protein α-amylase was added to a solution 
containing its ELP-conjugated cognate ligand, the transition temperature of the mixture 
increased by 5.5°C, consistent with the increase of surface hydrophilicity of the ELP 
conjugate complex [101]. Similarly, binding of calcium to ELP-conjugated calmodulin 
lowered the surface charge of the protein, thus triggering aggregation of the conjugate 




KNOB:HOLE INTERACTIONS CONFER FIBRIN AFFINITY 
 
For this chapter, we examine the fibrin(ogen) binding dynamics of a model knob-
displaying non-fibrin protein. Knob:hole interactions have been extensively studied over 
the past three decades using synthetic knob peptide mimics or knob-displaying fibrin 
fragments (refer to section 2.1.2 for details). Comparatively fewer papers deal with the 
study of knob:hole interactions in the context of non-fibrin proteins, much less the 
interaction of such knob-protein conjugates within a fibrin matrix. Nonetheless, the 
potential exists to exploit these stable and specific interactions as targeting modules for 
fibrin(ogen).  
In one early attempt, Kuyas and Doolittle synthesized alkylamine derivatives of 
GPRP that were designed to bind to human serum albumin via their hydrophobic alkane 
groups [132]. While the GPRP-amidoalkanes were shown to be functional in the presence 
of albumin, it was not clear if the hydrophobic interaction between the alkane tail and 
albumin was strong enough to increase the residence time of the derivative peptide for the 
application of this system as an anticoagulant. Thus in a separate project, the A chain 
remnant peptide of two-chain urokinase-type plasminogen activator (tcuPA) was replaced 
by a GPRP-containing synthetic peptide in order to confer fibrin clot specificity, thereby 
reducing undesirable systemic activation of plasminogen [133]. The increased affinity of 
the GPRP-conjugated uPA for fibrin purportedly reduced the concentration of activator 
necessary to achieve the same fibrinolytic rate by five-fold. Similarly, Hua et al. 
expressed GPRP on the N-terminus of low molecular weight single-chain uPA and 
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analyzing relative fibrinolytic rates, suggested that the fusion had a six-fold greater 
affinity for fibrin clots [134]. Unfortunately, none of these papers directly characterized 
the affinity between the GPRP-fused protein and fibrinogen or fibrin. 
Here, we hypothesized that non-fibrin proteins presenting knob sequences can be 
produced recombinantly and will bind stably and specifically to fibrinogen and fibrin via 
knob:hole interactions. We speculate that the stable knob:hole interaction should permit 
the retention of the knob-protein fusion within fibrin matrices. The model protein, 
FNIII9-10, was used to develop and optimize the expression system for the production of 
recombinant knob-displaying proteins.  
The results obtained from this project were published in 2010 in Biomaterials 
31(7): 1944-54 [135]. 
3.1.  Experimental Design 
We developed a platform system to rapidly clone and express recombinant 
proteins displaying different tetrapeptide sequences (GPRP, GPRV, GHRP) on their N-
termini, thus mimicking the knob display configuration on activated fibrin molecules. 
The pGEX4T-1 vector from GE Healthcare encodes an N-terminal glutathione S-
transferase (GST) tag followed by a thrombin cleavage site and a multiple cloning site 
(MCS). The cleavage site was mutated to code for the desired tetrapeptide sequences that 
would be exposed following thrombin cleavage. The coding frame of FNIII9-10 was then 
inserted into the multiple cloning site. This model protein is amenable to recombinant 
protein production [136, 137], has a known structure [138], is recognized by specific 
antibodies available commercially [136, 137], and does not contain any fibrinogen/fibrin 
binding sites . 
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The affinity of the different knob-FNIII9-10 conjugates towards immobilized 
fragment D was initially evaluated using surface plasmon resonance (SPR) to determine 
their relative equilibrium dissociation constant (KD). The specificity of the interaction 
between immobilized GPRP-FNIII9-10 and fibrinogen was then evaluated using enzyme-
linked immunosorbent assay (ELISA). The retention of GPRP-FNIII9-10 within fibrin 
matrices was then evaluated using a release assay with fixed sampling intervals. 
3.2.  Materials and Methods 
3.2.1.  Modification of pGEX4T-1 
The original thrombin cleavage site in the pGEX4T-1 vector (GE Healthcare, 
Piscataway, NJ) was modified from LVPR↓GSPE to LVPR↓GPRV, LVPR↓GPRP and 
LVPR↓GHRP using the QuikChange® II-E Site-Directed Mutagenesis Kit (Stratagene, 
La Jolla, CA). All plasmids were introduced to and maintained in the electro-competent 
XL-1 Blue E. coli strain provided and cultured in LB + ampicillin plates at 37°C. 
Plasmids were extracted from cultures using the QIAquick Spin Miniprep Kit (QIAGEN, 
Valencia, CA) and verified via sequencing (Johns Hopkins Synthesis & Sequencing 
Facility, Baltimore, MD). 
3.2.2.  Amplification and Insertion of FNIII9-10 into Expression Vectors   
The fibronectin type III domain 9-10 (FNIII9-10) was used as the model protein. 
The SalI site in the MCS was used to insert the FNIII9-10 open reading frame into the 
pGEX4TGSPE, pGEX4TGPRV, pGEX4TGPRP and pGEX4TGHRP vectors obtained above 
using standard molecular cloning techniques (enzymes purchased from NEB, Ipswich, 
MA). Briefly, the FNIII9-10 open reading frame was amplified in a high fidelity 
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polymerase chain reaction with Phusion High Fidelity DNA polymerase from the 
previously established pGEX4T-1-FNIII9-10 plasmid [136] using primers with flanking 
SalI sequences (underlined) and introducing Gly-Gly-Cys (bold) on the C-terminal if 
necessary: ACTGGTCGACTGGGTCTTGATTCCCCAACT and 
ACTGGTCGACTCAGCAACCACCTGTTCGGTAATTAATGGA. Vectors and insert 
were digested with SalI. The vectors were additionally dephosphorylated using heat-
deactivate-able Antartic phosphatase to prevent self-ligation. The respective vectors and 
insert were ligated using T4 DNA Ligase and transformed into electro-competent XL-1 
Blue cells. Selection for successfully ligated plasmids containing the insert was made on 
LB + ampicillin plates. The orientation of the FNIII9-10 insert was verified by in-colony 
PCR-screening using forward or reverse primers on the plasmid in combination with an 
internal primer within the insert. Colonies with the insert in the correct orientation were 
grown up for plasmid extraction. All plasmids were verified via sequencing. 
3.2.3.  Protein Production and Purification 
Plasmids containing the FNIII9-10 insert were transformed into electro-competent 
BL21 E. coli and protein production of the GST-tagged proteins stimulated as 
recommended by the manufacturer.  Following appropriate culture, cells were pelleted by 
centrifugation at 4°C and resuspended in ice-cold PBS supplemented with protease 
inhibitor (Roche, Indianapolis, IN), then lysed by adding 1 mg/mL of lysozyme followed 
by sonication. 1% Triton X and 10 U/mL of DNase was added and the lysate further 
incubated for 30 min with gentle agitation. The cell lysate was cleared of cellular debris 
by centrifugation followed by filtration through a 0.22 µm pore filter. Purification of the 
recombinant proteins was performed following the manufacturer’s recommendation using 
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the ÄKTAFPLC with a GST Prep FF 16/10 column (GE Healthcare) for affinity 
purification of GST-tagged proteins. Washing and binding steps were done in filter-
sterilized PBS and elution completed with glutathione (GSH) buffer (50 mM Tris-HCl, 
10 mM reduced GSH, pH 8.0). The GSH buffer was then exchanged to PBS using an 
Amicon Ultra-15 centrifugal filter with MWCO 10,000 (Millipore, Billerica, MA). The 
GST-tagged protein was incubated overnight with bovine thrombin (MP Biomedicals, 
Solon, OH) dosed at 10 U per mg recombinant protein and the cleaved protein solution 
was reintroduced on the GST Prep FF 16/10 column to remove the GST tag, followed by 
the HiTrap Benzamidine FF column (GE Healthcare) to remove thrombin. Gxxx-FNIII9-
10-(C) proteins were assessed for purity by SDS-PAGE and quantitated at Abs280nm using 
the Nanodrop 1000 (Thermo Scientific, Wilmington, DE) using extinction coefficients 
calculated using an online peptide property calculator (found at 
http://www.basic.northwestern.edu/biotools/proteincalc.html), then aliquoted and stored 
at -80°C until use. 
3.2.4.  ELISA Binding Assays 
A modified ELISA technique was used to establish the affinity of fibrinogen for 
the various Gxxx-FNIII9-10-C proteins covalently immobilized on maleimide-activated 
plates via their C-terminal cysteines. Sulfhydryl-containing proteins/peptides were added 
to pre-blocked maleimide-activated 96-well plates (Pierce, Thermo Scientific, Rockford, 
IL) at 10 µg/mL in conjugation buffer (CB) comprising 150 mM NaCl, 100 mM 
phosphate, 10 mM EDTA, pH 7.2, with attachment occurring via maleimide-sulfhydryl 
(thioether) linkages. TCEP (1 mM) was added to maintain sulfhydryl groups in the 
reduced form. Following, unreacted maleimide groups were quenched with 20 µg/mL 
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cysteine in CB.  Human fibrinogen (25 µg/mL) was incubated with the substrates and 
unbound protein removed by washing.  Bound fibrinogen was detected using HRP-
conjugated goat anti-fibrinogen antibody (MP Biomedicals #55239) and 1-StepTM Ultra 
TMB-ELISA (Pierce).  The TMB reaction was quenched with 1 M H2SO4 before 
measuring the Abs450nm using the SpectraMax M2 (Molecular Devices, Sunnyvale, CA). 
All intervening wash steps were conducted using washing buffer (WB) comprising 150 
mM NaCl, 100 mM phosphate, 0.05% Tween-20, pH 7.2; all binding steps were 
conducted using binding buffer (BB) comprising PBS + 1% BSA. For basic affinity 
assays, the concentration of the fusion proteins was varied. For specificity assays, varying 
concentrations of Gxxx tetrapeptides (Genscript, Piscataway, NJ) were added to the 
fibrinogen solution during incubation with the covalently immobilized proteins.  
3.2.5.  Biotinylation of Gxxx-FNIII9-10 Proteins 
Gxxx-FNIII9-10-C proteins were conjugated via the sulfhydryl group of the C-
terminal cysteine to maleimide-functionalized biotin (maleimide-PEG2-biotin; Pierce 
#21902) following the manufacturer’s recommended protocol. Unreacted maleimide-
PEG2-biotin was removed using Slide-A-Lyzer dialysis cassettes with MWCO 3,500 
(Pierce). The extent of biotinylation was determined using the Pierce Biotin Quantitation 
Kit (Pierce). 
3.2.6.  Fibrin Clotting Assays 
Clotting was initiated in a 96-well plate format and the Abs350nm used as a 
standard measure of turbidity. Briefly, increasing doses of the Gxxx-FNIII9-10-biotin 
proteins were preincubated with 4 mg/mL human fibrinogen (ERL #FIB3) in Tris+Ca 
buffer (140 mM NaCl, 5 mM CaCl2, 20 mM Tris, pH 7.4). Following the 1 h 
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preincubation, clotting was initiated by adding 1 NIHU/mL of human thrombin (ERL) or 
batroxobin moojeni (Centerchem, Norwalk, CT), and 1 U/mL human FXIIIa (kindly 
donated by Baxter AG, Vienna Austria). Real time measurements of clot turbidity were 
taken every minute for 1 h. To determine the amount of unclotted protein, the clots were 
spun down and the supernatant or clot liquor was analyzed for total protein using the 
Quant-iT protein assay (Invitrogen, Carlsbad, CA).  
3.2.7.  Rheological Assays 
The Bohlin CVO 120 high resolution rheometer (Malvern Instruments, 
Westborough, MA) with plate-plate geometry was used to assess the viscoelastic 
characteristics of fibrin clots at room temperature. Briefly, fibrinogen (preincubated with 
or without Gxxx-FNIII9-10-biotin as indicated) and enzyme mixtures with identical 
compositions as those used in the turbidity and clottability assays were mixed by 
pipetting and immediately added to the bottom plate. The upper plate (14 mm diameter) 
was immediately lowered to a gap size of 1 mm and the mixture was allowed to 
polymerize for 30 min in a humid chamber. Following, oscillating measurements were 
taken over a frequency range of 0.05 to 1.0 Hz at a constant strain of 0.5%.  
3.2.8.  Protein Release Assays 
Analogous to the clotting assays, Gxxx-FNIII9-10-biotin was preincubated with 
fibrinogen in Tris+Ca buffer in 2 mL conical bottom tubes. Clotting was initiated by 
adding thrombin or batroxobin, and FXIIIa. After a one-hour incubation, the resulting 
clot was overlaid with 1 mL Tris+Ca buffer. The entire volume of buffer was removed 
and replaced with fresh buffer at 1, 4, 8, 12, 24, 48, 72, 96-h timepoints for analysis. 
Gxxx-FNIII9-10-biotin proteins in the recovered supernatant samples were quantitated 
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using a sandwich ELISA. Briefly, 96-well ELISA plates were coated with 5 µg/mL 
streptavidin, then washed and blocked with 1% BSA. The sample, mouse monoclonal 
anti-FNIII9-10 antibody (HFN7.1; Developmental Studies Hybridoma Bank, Iowa City, 
IA) and HRP-conjugated goat anti-mouse antibody (Pierce #1858413) were added 
sequentially to the plate with intervening wash steps. TMB was added to react with the 
HRP and the reaction quenched with 1 M H2SO4 before measuring the Abs450nm.  
3.2.9.  Statistical Analysis 
All experimental data are reported as mean ± SEM of at least 3 independent 
triplicate experiments. Results were analyzed using GraphPad PRISM 5.0. Statistical 
comparisons for all experimental sets were based on one-way ANOVA using the Tukey 
post-hoc test for pair-wise comparisons with significance defined by p < 0.05. 
3.3.  Knob-FNIII9-10 Preparation 
We developed an expression vector system allowing the simple and rapid cloning 
of any gene-of-interest into a series of vectors that facilitates the production of any 
proteins-of-interest with any of three N-terminal fibrin knob sequence – GPRP, GPRV, 
GHRP.  
3.3.1.  Vector Development 
The commercially available pGEX4T-1 expression vector is designed for the 
IPTG-induced expression of proteins with an N-terminal 26 kDa GST tag under control 
of the tac promoter.  This tag can then be removed via thrombin cleavage, analogous to 
the process of fibrinogen activation wherein protein segments are proteolytically cleaved 
from the N-termini of the Aα and Bβ chains.  
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Using the unmodified pGEX4T-1 vector, the N-terminal sequence exposed upon 
thrombin cleavage of the expressed GST-tagged protein is GSPE, which does not bind to 
fibrin pockets. We modified this coding sequence on the expression vector to each of the 
desired tetrapeptide sequences using site-directed mutagenesis (Figure 2A). Site-directed 
mutagenesis was conducted using a commercially available kit that employs a PCR-based 
method of introducing base-pair substitutions, insertions or deletion on any plasmid 
vector in vitro.  
The coding sequence for our model protein, the 20 kDa FNIII9-10 fragment, was 
then introduced into the MCS using standard molecular cloning techniques. Notably, the 
repeating modules of fibronectin, frequently described as having a beads-on-a-string 
structure, represent individually folded domains that should be amenable to tagging at the 
N- and C-termini. In some versions, the primers used for insertion of the FNIII9-10 open 
reading frame included the coding sequences for a C-terminal glycine-glycine-cysteine as 
an additional functional handle. Since FNIII9-10 does not contain any cysteine residues, 
this C-terminal cysteine provides a specific site for the sulfhydryl-targeted conjugation of 




Figure 2. Gxxx-FNIII9-10 protein production and purification. (A) Molecular engineering of the 
pGEX4T-1 vector to express proteins with variable thrombin cleavage sites, LVPR↓Gxxx. Site-
directed mutagenesis was used to modify the coding sequence for the thrombin cleavage site (T). 
Next, the open reading frame of the protein-of-interest, FNIII9-10, was inserted into the multiple 
cloning site (MCS). The expressed proteins comprise an N-terminal glutathione S-transferase (GST) 
tag, followed by the thrombin cleavage site and protein-of-interest. (B) Coomassie-stained SDS-
PAGE gel demonstrating protein purity at the different stages of purification using affinity 
chromatography. GST-tagged Gxxx-FNIII9-10 (lane 2) was purified from contaminating proteins in 
the bacterial cell lysate (lane 1) via the GST affinity column. Thrombin-catalyzed cleavage releases 
the 26 kDa GST-tag from the 20 kDa Gxxx-FNIII9-10 protein (lane 3). Next, the thrombin and GST-
tag were removed using benzamidine and GST affinity columns respectively, leaving the desired 
protein-of-interest (lane 4). 
 
 
3.3.2.  Protein Production and Purification 
The GST-tagged proteins were expressed in the protease-deficient protein 
expression E. coli strain BL21 upon IPTG induction. Figure 2B shows a representative 
Coomassie-stained SDS-PAGE gel illustrating product purity at the different stages of 
protein purification using affinity purification via the ÄKTApurifier system. Notably, the 
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GST tag serves dual purposes as affinity tag and a measure of thrombin cleavage 
efficacy. Impaired thrombin cleavage efficiency due to modification of the thrombin-
cleavage site was not encountered for these proteins. 
Using this platform cloning and expression system we successfully expressed and 
purified the following knob-protein fusions: GSPE-FNIII9-10, GSPE-FNIII9-10-C, 
GPRP-FNIII9-10, GPRP-FNIII9-10-C, GPRV-FNIII9-10, GPRV-FNIII9-10-C, GHRP-
FNIII9-10, GHRP-FNIII9-10-C. 
3.4.  Characterizing Fibrinogen/Fibrin Affinity 
Initial SPR data collected by Stabenfeldt indicated that GPRP-FNIII9-10 was the 
strongest binder (KD = 3.0 ± 0.1 µM) to fibrinogen [135]. This finding was not surprising 
in light of the fact that the GPRP peptide binds to fibrinogen with the highest affinity (KD 
~20 µM) out of the three knob peptide sequences used in this work [139, 140]. Further 
investigations were therefore conducted using the high affinity GPRP-FNIII9-10 and the 
non-binding control GSPE-FNIII9-10. 
The binding strength and specificity of the knob-protein fusions for fibrinogen 
was evaluated using ELISA. The knob-protein fusions were then added to fibrin matrices 
at sufficiently low molar ratios so as not to perturb fibrin polymerization dynamics and 
clot structure. The retention of the knob-protein fusions within fibrin matrices was 
evaluated using a standard protein release assay. 
3.4.1.  Evaluating GPRP-FNIII9-10 Affinity Using ELISA 
Gxxx-FNIII9-10-C proteins were immobilized on maleimide-activated 96-well 
plates via maleimide-sulfhydryl chemistry, allowing the unidirectional presentation of 
their N-terminal knobs to fibrinogen-containing solutions in the wells. Using standard 
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ELISA techniques, the bound fibrinogen was detected using an anti-fibrinogen HRP-
conjugate, with stronger signals corresponding to increased amounts of bound fibrinogen. 
Complementing the earlier SPR data, the ELISA results indicate that soluble fibrinogen 
bound to immobilized GPRP-FNIII9-10-C but not the control, GSPE-FNIII9-10-C 
(Figure 3A). This demonstrates the mechanism of action, that fibrinogen binds the knob-
protein fusion via the knob sequences and not via interaction with the fibronectin 
domains in our model protein.  
 
 
Figure 3. ELISA studies analyzing GPRP-FNIII9-10 affinity for fibrinogen. (A) Affinity assays 
demonstrating binding between immobilized GPRP-FnIII9-10-C, but not GSPE-FnIII9-10-C, and 
fibrinogen. ELISA plate readouts (Abs450nm) were normalized against the maximum signal obtained 
using GPRPFPAC peptide (Genscript) at a coating concentration of 20 µg/mL. (B) Specificity assays 
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demonstrating that GPRP and GPRV peptides compete with immobilized GPRP-FNIII9-10 for 
fibrinogen. ELISA plate readouts were normalized against the signals obtained in the presence of the 




To further demonstrate specificity, synthetic fibrin knob peptides were added in 
large molar excess (102- to 104-fold) to the fibrinogen solution that was to be incubated 
with immobilized GPRP-FNIII9-10-C. As expected, free GPRP tetrapeptides competed 
with the immobilized GPRP-FNIII9-10-C for binding to fibrinogen, resulting in a dose-
dependent inhibition of fibrinogen binding following a one-hour pre-incubation (Figure 
3B). These results suggest that the GPRP sequence is the mediator of the interaction 
between the immobilized protein and fibrinogen.  
The tetrapeptides GPRV and GHRP are also known to bind the same fibrinogen 
holes via knob:hole interactions, albeit with slightly different affinities and specificities 
[10]. Our results indicate that GPRV competed with GPRP-FNIII9-10 for binding to 
fibrinogen, but to a lesser extent as compared to GPRP, while GHRP was not a 
significant competitor to GPRP-FNIII9-10 under our experimental conditions. Notably, 
these results agreed with our SPR data suggesting that the affinity constant of GPRV-
FNIII9-10 was at least an order of magnitude smaller than that of GPRP-FNIII9-10, while 
GHRP-FNIII9-10 had little affinity for immobilized fibrinogen fragment D [135]. These 
results therefore support the interpretation that the interaction between the GPRP-FNIII9-
10 protein and fibrinogen is primarily mediated by the respective N-terminal tetrapeptide 
sequences through specific interactions with fibrinogen holes. 
3.4.2.  Fibrin Assembly in the Presence of GPRP-FNIII9-10 
 37 
Since knob-protein fusions inherently exploit the knob:hole interactions involved 
in fibrin assembly, we first verified that the presence of the GSPE-FNIII9-10-biotin and 
GPRP-FNIII9-10-biotin conjugates did not significantly impede the clotting process or 
alter global matrix characteristics at the dosages used for the matrix release assays.  
GPRP-FNIII9-10-C was conjugated to maleimide-functionalized biotin, 
generating GPRP-FNIII9-10-biotin conjugates that can be quantitated via sandwich 
ELISA. GPRP-FNIII9-10-biotin proteins were preincubated with fibrinogen before 
clotting was induced by the addition of FXIIIa and either thrombin (exposes both knobs 
‘A’ and ‘B’) or batroxobin (exposes knobs ‘A’ only). The process of fibrin assembly can 
be inferred from the gross absorbance of the fibrinogen-containing mixture since the 
lateral aggregation of protofibrils during clotting results in a rapid rise in turbidity [46]. 
The turbidity curves obtained suggest that fibrin assembly in the presence of thrombin 
(Figure 4A) or batroxobin (Figure 4B) was not significantly impacted by the presence of 
GPRP-FNIII9-10-biotin, or the control GSPE-FNIII9-10-biotin, at the 
conjugate:fibrinogen molar ratio of 1:10. In comparison, the difference in turbidity 
profiles for thrombin- versus batroxobin-catalyzed clots is a clear reflection of 
mechanistic differences between the two enzymes. 
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Figure 4. Fibrin assembly in the presence of GPRP-FNIII9-10 and GSPE-FNIII9-10. Clots were 
formed from 6 µM (= 2 mg/mL) fibrinogen solutions containing 0.6 µM GPRP-FNIII9-10-biotin or 
GSPE-FNIII9-10-biotin upon the addition of 1 U/mL FXIIIa and 1 NIHU/mL human α-thrombin or 
batroxobin moojeni. Control clots were formed in the absence of the conjugates. (A) Turbidity curves 
obtained in the presence of thrombin. (B) Turbidity curves obtained in the presence of batroxobin. 
(C) Complex moduli of the clots after 30 min clotting time. Measurements were taken at a frequency 
of 0.22 Hz and strain of 0.5%. (D) Quantitation of soluble protein in the clot liquor from clots after 1 




Rheological assaying of clots formed following a 30-minute clotting time 
suggests that the presence of either conjugate did not significantly affect the native 
viscoelastic properties of the clots (Figure 4C).  Moreover, quantitation of the soluble 
proteins in the clot liquor (the remaining supernatant after spinning down the insoluble 
fibrin) also indicates that the presence of GPRP-FNIII9-10-biotin, or the control GSPE-
FNIII9-10-biotin, did not significantly impact the clottability of the mixture (Figure 4D). 
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These results agree with past research showing that at least a 100-fold excess of the 
GPRP tetrapeptide was necessary to completely inhibit fibrin assembly [139] and suggest 
that the presence of knob-protein fusions will not significantly interfere with the 
formation of the fibrin matrix at the loading concentration used.  
3.4.3. Retention in Fibrin Matrices Using Release Assays  
We proceeded to examine the retention of GPRP-FNIII9-10-biotin conjugates 
within three-dimensional fibrin matrices by monitoring protein release from the clots into 
the surrounding buffer reservoir. In particular, we were interested in observing the release 
profiles from both normal thrombin-catalyzed clots and batroxobin-catalyzed clots. 
Batroxobin selectively exposes the knobs ‘A’ but not knobs ‘B’, theoretically leaving 
unoccupied fibrinogen holes that should be available for binding to GPRP-FNIII9-10-
biotin, thus promoting its retention within the fibrin matrix.  
As described in the previous section, the GPRP-FNIII9-10-biotin conjugates were 
preincubated with fibrinogen at a 1:10 molar ratio (conjugate:fibrinogen), before clotting 
was induced by the addition of FXIIIa and either thrombin or batroxobin. After a one-
hour incubation period, the clot was overlaid with pre-warmed buffer and incubated at 
37°C with agitation. Samples taken at regular intervals were evaluated for the presence of 
fibrin(ogen) and conjugate via sandwich ELISAs. In particular, the HFN7.1 
conformation-specific antibody was used against the conjugates to demonstrate that the 
conformational integrity of the FNIII9-10 was preserved during the release assay. 
Moreover, GPRP-FNIII9-10-biotin is capable of binding to ELISA plates coated with 
fibrinogen and being detected by the same antibody (data not shown), indicating that the 
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Figure 5. Release of GPRP-FNIII9-10 versus GSPE-FNIII9-10 from thrombin- or batroxobin-
catalyzed fibrin clots. Clot compositions as described in Figure 4. 200 µL clots were overlaid with 1 
mL Tris+Ca buffer and samples were taken at the designated timepoints over 4 days. (A, B) 
GPRP/GSPE-FNIII9-10-biotin measured in the samples taken from thrombin-catalyzed clots and the 





The amount of soluble fibrin(ogen) in all the samples remained below the 
detection limit (~10 ng/mL) of the fibrin(ogen) ELISA, indicating that the clots remained 
intact during the four-day incubation period (data not shown). From the FNIII9-10-biotin 
ELISA, we found that less GPRP-FNIII9-10-biotin was released within the first 24 hours 
as compared to GSPE-FNIII9-10-biotin for both the thrombin (Figure 5A,B) and 
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batroxobin (Figure 5C,D) clots, suggesting that the affinity between GPRP-FNIII9-10-
biotin and fibrin(ogen) was able to retard the initial ‘burst release’ of protein from the 
fibrin matrix, resulting in an overall greater retention of the loaded protein within the clot. 
Nonetheless, statistical comparisons of the absolute quantity of protein released at each 
time point did not reveal significant differences between GPRP-FNIII9-10-biotin and 
GSPE-FNIII9-10-biotin release, particularly after the initial 24-hour burst release. Rather, 
more significant differences were found between the amounts of protein released from 
thrombin- versus batroxobin-catalyzed clots for both GPRP-FNIII9-10 (Figure 6A, B) 
and GSPE-FNIII9-10 (Figure 6C, D), suggesting that other factors may be involved in 
mediating protein retention past the 24-hour time point. In particular, fibrin clots formed 
under the catalysis of different enzymes and at different enzyme concentrations are 




Figure 6. Release of GPRP-FNIII9-10 or GSPE-FNIII9-10 from thrombin- versus batroxobin-
catalyzed fibrin clots. Clot compositions as described in Figure 4. 200 µL clots were overlaid with 1 
mL Tris+Ca buffer and samples were taken at the designated timepoints over 4 days. (A, B) GPRP-
FNIII9-10-biotin measured in samples taken from thrombin- or batroxobin-catalyzed clots and the 




3.5.  Discussion and Conclusions 
We were able to successfully produce and purify recombinant fibrin-binding 
proteins with the generalized structure Gxxx-protein-(C), capitalizing on the N-terminal 
Gxxx sequence for protein retention within fibrin and the C-terminal cysteine as a 
functional handle. As proof-of-concept, we found that the high affinity GPRP sequence 
facilitates the specific binding of such fusion proteins to fibrinogen although it appeared 
that GPRP-FNIII9-10 was not retained to a significant extent within fibrin matrices past 
the 24-h timepoint.  
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It is possible that the fibrin-binding capacity of the GPRP-FNIII9-10-biotin 
conjugate was diminished when presented in a three-dimensional system of both fibrin 
holes and competing native fibrin knobs. Thus, Stabenfeldt developed a microfluidic 
perfusion system that allowed the real-time monitoring of protein incorporation, 
retention, and release within fibrin matrices to assist with our interpretation of the 
system’s strengths and limitations [135]. Fibrin clots, pre-loaded with Alexa Fluor 633-
labeled knob-protein fusion, were formed under similar conditions as used in the previous 
release assays and vigorously perfused to create a temporally-accelerated release system 
that could be monitored in real-time using confocal microscopy. Results from these 
studies showed that the high affinity binder GPRP-FNIII9-10-AF633, but not the control 
GSPE-FNIII9-10-AF633, was colocalized with the Alexa Fluor 555-labeled fibrin fibers. 
Following a rigorous 30-min perfusion (at 10 µL/min) of buffer, 12.8% of the fibrin 
matrix remained colocalized with GPRP-FN9-10-AF633, compared to 0.1% for the 
control, demonstrating a robust interaction between the fusion and fibrinogen. 
We speculate that the retention characteristics of such knob-protein fusions may 
be further improved by increasing the overall affinity constant through the use of stronger 
fibrin-binding sequences or by introducing multivalency. In particular, we note that 
previous research using a heparin-based affinity system for the retention of proteins in 
fibrin matrices via non-covalent interactions with similar affinities (KDs in the µM range) 
suggest that a large (~thousand-fold) excess of binding sites is necessary to successfully 
retain such proteins within the fibrin matrix [141]. This poses a potential limitation for 
the use of single knob:hole interactions for the retention of proteins in fibrin matrices 
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since the number of available pockets is limited by fibrinogen concentration as well as 
the presence of competing knobs.  
On the other hand, this work offers valuable insight into the significance behind 
the multimeric nature of the native fibrin(ogen) molecule, comprising up to four fibrin 
knobs (two knob ‘A’ and two knob ‘B’) per fully activated molecule. Specifically, 
suitably tagged recombinant proteins with pre-defined N-terminal sequences can be used 
as tools to bridge the current informational gap between studies utilizing short synthetic 
peptides and those focusing on multimeric fibrin fragments, particularly since the 
physiological relevance of each type of knob:hole interaction (A:a, A:b, B:a, B:b) to 
fibrin assembly remains controversial to this day. 
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CHAPTER 4 
ALTERING FIBRIN NETWORK MORPHOLOGY 
 
For this chapter, we are interested in evaluating the impact of fibrin knob-
displaying flexible polymer linkers on polymerization dynamics, FXIIIa-catalyzed 
crosslinking, fibrin network structure and clot stiffness. Fibrin network structure is 
strongly dependent upon fibrinogen, thrombin and calcium concentrations [47]. In 
particular, the knob:hole interactions initiated by the removal of fibrinopeptides are 
instrumental in determining key network parameters such as fiber diameter and branching 
density, both of which may be inferred from clot turbidity measurements [46].  
The addition of knob peptide mimics such as GPRP and GHRP perturbs clot 
turbidity and fibrin matrix formation in slightly different ways. GPRP-derived mimics 
inhibit fibril assembly through competitive binding, disrupting knob:hole interactions and 
increasing fibrinogen clotting time [139, 142]. On the other hand, GHRP-derived mimics 
enhance clot turbidity and delay plasmin-induced clot degradation presumably due to 
activation of αC domains enabling an alternative αC-αC based polymerization 
mechanism [61, 143].  
Yet bivalent 900 Da GPRP2-PEG conjugates were found to promote the end-to-
end crosslinking of fibrinogen γ chains by FXIIIa [42], suggesting that the PEG linker 
tethered the adjacent holes ‘a’, contributing to the assembly of fibrinogen favoring FXIIIa 
activity. Thus, we propose the conjugation of sulfhydryl-terminated GPRPAAC peptides 
to the maleimide-terminated ends of different PEG structures, creating multivalent 
GPRPn-PEG linkers capable of perturbing fibrin matrix structure through knob:hole 
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interactions. This unique non-covalent means of altering matrix structure should preserve 
the physiological complexity of the original protein while allowing the independent 
control of matrix mechanical properties by altering conjugate size and valency. We 
hypothesize that these distance-spanning GPRPn-PEG conjugates will interact with 
soluble fibrinogen and fibrin monomer and impose structural changes to the fibrin 
polymer network structure generated in the presence of thrombin and/or FXIIIa. 
The results obtained from this project were published in 2011 in Biomaterials 
32(19): 4406-14 [144]. 
4.1.  Experimental Design 
Based on literature and our experience (see Chapter 3), the knob ‘A’ mimic, 
GPRP, has been shown to exhibit the most reproducible binding to fibrinogen pockets 
under different experimental conditions. This study continues to employ GPRP as the 
fibrin(ogen)-binding peptide and introduces GPSP as the non-binding control. The most 
commonly used PEG structures in current FDA-approved PEG conjugates are 
monofunctional linear PEG chains with sizes ranging from 5 kDa to 20 kDA, and 
branched PEG chains 40 kDa in size [69]. In keeping with this working range, the 
following maleimide-activated PEG varieties were used: 2, 3.5, 5, 7.5 kDa bifunctional 
MAL2-PEG, and 2, 10, 20 kDa tetrafunctional MAL4-PEG. 
The effect of these multivalent knob-PEG conjugates on fibrin polymerization, 
network morphology, and fibrinolysis was examined in relation to the unconjugated knob 
peptide. The impact of these multivalent conjugates on FXIIIa crosslinking and clot 
stiffness was also evaluated. 
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4.2.  Materials and Methods 
4.2.1.  Sulfhydryl-Maleimide Conjugation 
Sulfhydryl-containing cysteine-terminated peptides (GPRPAAC and the control 
peptide GPSPAAC) were custom-ordered from Genscript (Piscataway, NJ) in pre-
aliquoted and lyophilized form. Maleimide-activated components used were namely, 2, 
3.5, 5, 7.5 kDa maleimide-PEG-maleimide, and 2, 10, 20 kDa 4-arm PEG maleimide 
(sourced from JenKem Technology, Allen, TX;  2 kDa 4-arm PEG from Creative 
PEGWorks, Winston Salem, NC). 
The conjugation buffer comprised 100 mM phosphate buffer pH 7.2, 150 mM 
sodium chloride, 10 mM EDTA. Desired quantities of sulfhydryl-containing peptide and 
the maleimide-activated components were reacted in a 1.5:1 molar ratio and the reaction 
was monitored using Ellman’s assay for free sulhydryls (Thermo Fisher Scientific, 
Waltham, MA). Reactions were generally complete within 2 h. Excess unconjugated 
peptide was removed from the conjugated product using Slide-A-Lyzer dialysis cassettes 
(Thermo Fisher Scientific) and deionized water as the exchange buffer. The product was 
aliquoted, then lyophilized and quantified. 
The lyophilized conjugates were resuspended in water before use and analyzed 
for their PEG and amine components. PEG was quantified using the method of Sims and 
Snape and modified for a 96-well format [145]. Briefly, 80 µL of sample and 20 µL of 
5% barium chloride solution (in 1 M HCl) were added sequentially to each well of a 96-
well plate. 10 µL 0.1 N iodine solution was then added before taking the absorbance 
readings at 535 nm (Abs535nm). 10 kDa PEG (Sigma, St Louis, MO) was used as the 
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calibration standard. Amines were quantified using the CBQCA assay kit (Invitrogen, 
Carlsbad, CA) with the respective peptides used to generate the standard curve.  
4.2.2.  Fibrin Polymerization and Degradation 
Enzyme-catalyzed polymerization of mixtures of fibrinogen and GPRPn-PEG, or 
control GPSPn-PEG, conjugates was initiated in 96-well plates. Briefly, 10 µL of the 
conjugate and 40 µL of 2.5 mg/mL human fibrinogen (FIB-3; Enzyme Research 
Laboratories, South Bend, IN) were pre-incubated for 1 h. Following, 50 µL of 0.5 
NIHU/mL human α-thrombin and 10 Loewy units/mL human FXIIIa (both from Enzyme 
Research Laboratories) were added to the fibrinogen mixture to initiate polymerization. 
The turbidity (Abs350nm) of the mixtures was followed using a plate reader. To determine 
the amount of unclotted protein, the isolated clot liquor was analyzed for total soluble 
protein using the Quant-iT protein assay (Invitrogen). To obtain clot degradation profiles, 
100 µL 0.01 mg/mL human plasmin (Enzyme Research Laboratories) was overlaid on the 
100 µL clots in 96-well plates and agitated on the Eppendorf MixMate at 400 rpm. 
Turbidity readings and 5 µL sample aliquots were taken at 1, 3, 5, 7, 9-h timepoints for 
analysis of total soluble protein using the Quant-iT protein assay. All reactions were 
conducted in buffer comprising 25 mM Tris-HCl pH 7.5, 137 mM NaCl, 5 mM CaCl2. 
4.2.3.  Crosslinking Assays 
Coomassie-stained SDS-PAGE gels and Western blots were used to quantitatively 
and qualitatively assess the extent of FXIIIa-catalyzed crosslinking in fibrin clots. 
Briefly, mixtures of fibrinogen and GPRPn-PEG, or control GPSPn-PEG, conjugates were 
prepared as described in the turbidity assays. The mixtures were allowed to polymerize 
following enzyme addition for 1 h, followed by boiling for 5 min to quench further 
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reaction. An equal volume of 2X Laemmli buffer (Biorad, Hercules, CA) containing 5% 
beta-mercaptoethanol was added to the clots, which were further vortexed and boiled to 
ensure complete dissolution. Samples were electrophoresed on 10% SDS-PAGE gels. 
SimplyBlue (Invitrogen) was used for Coomassie-staining of the gels following the 
manufacturer’s protocol. The stained gel was imaged using the Odyssey infrared imaging 
system (LI-COR, Lincoln, NE) in the 700 nm channel. The bands corresponding to the 
monomeric α, β, and γ chains on the Coomassie-stained gels were quantified using 
ImageJ, normalized against the non-crosslinkable β chain in each sample, then 
normalized against the uncrosslinked negative control samples run on each gel.  
For Western blots, the proteins were transferred to Immobilon-FL PVDF 
membranes (Millipore, Billerica, MA) overnight. Following, the membranes were 
blocked with IR Blocking Buffer (Rockland, Gilbertsville, PA) and probed separately for 
the fibrinogen α chain (primary: sc-33917 from Santa Cruz Biotechnology, Santa Cruz, 
CA; secondary: IRDye 800CW donkey anti-goat IgG from LI-COR) and fibrinogen γ 
chain (primary: sc-133157 from Santa Cruz Biotechnology; secondary: IRDye 680LT 
donkey anti-mouse IgG from LI-COR). The membrane was stripped between blotting by 
incubating with 6 M guanidine hydrochloride at 65°C until the antibody fluorescent 
signal was eliminated.  
4.2.4.  Rheological Assays 
The Bohlin CVO 120 high resolution rheometer (Malvern Instruments, 
Westborough, MA) with plate-plate geometry was used to assess the viscoelastic 
characteristics of fibrin clots at room temperature. Briefly, mixtures of fibrinogen and 
GPRPn-PEG, or control GPSPn-PEG, conjugates were prepared as described in the 
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turbidity assays. Following the addition of thrombin and FXIIIa, the solutions were 
mixed quickly by pipetting and immediately added to the bottom plate of the rheometer. 
The upper plate (14 mm diameter) was immediately lowered to a gap size of 1 mm and 
the mixture was allowed to polymerize for 1 h in a humid chamber. Following, oscillating 
measurements were taken over a frequency range of 0.05 to 1.0 Hz at a constant strain of 
0.5%. Each condition was tested with at least 8 samples.  
4.2.5.  Confocal Imaging 
Fluorescently-labeled fibrinogen was prepared by conjugation to the amine-
reactive Alexa Fluor 555 succinimidyl ester (Invitrogen) following the manufacturer’s 
recommendation. Clots containing 10% labeled fibrinogen were imaged using the Zeiss 
510 laser scanning confocal microscope (Carl Zeiss, Thornwood, NY). Mixtures of 
fibrinogen and GPRPn-PEG, or control GPSPn-PEG, conjugates were prepared as 
described in the turbidity assays. Following the addition of thrombin and FXIIIa, the 
solutions were mixed quickly by pipetting and immediately added to a glass slide. The 
mixture was overlaid with a glass coverslip supported by a 0.3 mm spacer. The open ends 
of the chamber were sealed with nail polish and the mixture allowed to polymerize within 
the chamber for 1 h before imaging. A 20-section Z-stack (10 µm slices) of the 89×89 µm 
field under the 100× objective was captured for reconstruction of the 3D network 
structure. At least 3 clots were formed independently for each condition, with 4 random 
samplings taken per clot. 
4.2.6.  Statistical Analysis 
All graphs and analyses were prepared in GraphPad PRISM 5.0. Results are 
presented as mean ± SD. Statistical comparisons for conjugate titration sets were based 
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on one-way ANOVA using the Tukey post-hoc test for pair-wise comparisons with 
significance defined by p < 0.05. Comparisons of conjugates and their paired controls 
(for crosslinking and rheological data) were made using the Student’s t-test. 
4.3.  Knob-PEG Preparation 
The initial phase of this work involved establishing a robust scheme for conjugate 
production and characterization. In particular, the preparation of PEGylated peptides 
posed special problems due to the small difference in molecular weight between the 
unreacted PEG (several thousand Da) and the conjugated PEG (with an additional 671 Da 
for GPRPAAC or 602 Da for GPSPAAC), leading to purification problems.  
4.3.1.  Conjugate Production 
The sulfhydryl-maleimide reaction is a highly efficient reaction resulting in a 
stable thioether linkage when carried out at pH 6.5-7.5. The maleimide-activated PEG 
products we purchased generally carried specifications of >95% purity, <1.03 
polydispersity, and >90% substitution. Similarly, the synthetic cysteine-containing 
peptides purchased were of >98% purity and stable in the reduced form (verified in-house 
using electrospray ionization mass spectrometry or ESI-MS). 
The reaction conditions specified a slight molar excess of peptide over maleimide 
such that the reaction goes to completion. The unreacted peptide was then removed via 
extensive dialysis into water, bypassing the more complex purification of the peptide-
PEG conjugate from unreacted PEG. The dialyzed product was then aliquoted, 
lyophilized and stored. 
4.3.2.  Conjugation Characterization 
 52 
The lyophilized product was resuspended in water and analyzed for protein and 
PEG concentration. The presence of the conjugated PEG moiety interferes with most 
commercially available protein quantitation assays (e.g. Pierce’s bicinchoninic assay,  
Invitrogen’s Quant-iTTM assay) but results from the detergent-tolerant CBQCA assay 
were the most consistent, showing a reproducible overestimation of peptide quantity in 
the presence of the peptide-PEG conjugate (Table 1). It is also duly noted that the 
CBQCA assay is sulfhydryl-sensitive and should only be used for the quantitation of 
conjugates following extensive dialysis to remove the excess unreacted peptide. 
 
Table 1. Fraction of peptide detected by the CBQCA assay 
Mixture composition Fraction of peptidea 
(2 h post-mixing) 
Fraction of peptidea 
(24 h post-mixing) 
PEG + GPRP 0.988 0.999 
PEG + GPRPAAC 0.604 0.843 
MAL-PEG + GPRP 1.128 1.142 
MAL-PEG + GPRPAAC 1.733 1.786 




PEG was quantified using the method of Sims and Snape employing barium 
chloride and iodine solution [145]. An alternative method proposed by Ghosh employing 
the extraction of ammonium ferrothiocyanate into chloroform [90, 146] was attempted 
initially but led to inconsistent results, particularly when PEG was conjugated to the 
charged GPRPAAC peptide. Attempts to troubleshoot the protocol, including the addition 
of proteases to digest the conjugated peptide or buffer substitution to neutralize the 
peptide charges, failed to yield more reproducible data. In contrast, the results from the 




Table 2. Characterization of peptide-PEG conjugates 
Conjugate % PEGa yield % Peptideb yield Peptide : PEG 
2 kDa GPRP2-PEG 89 190 6.41 
2 kDa GPSP2-PEG 62 14 0.71 
3.5 kDa GPRP2-PEG 88 199 6.75 
3.5 kDa GPSP2-PEG 80 31 1.18 
5 kDa GPRP2-PEG 66 188 8.47 
5 kDa GPSP2-PEG 69 30 1.30 
7.5 kDa GPRP2-PEG 63 198 9.35 
7.5 kDa GPSP2-PEG 59 28 1.44 
2 kDa GPRP4-PEG 57 73 3.83 
2 kDa GPSP4-PEG 57 60 3.18 
10 kDa GPRP4-PEG 77 385 14.92 
10 kDa GPSP4-PEG 61 52 2.57 
20 kDa GPRP4-PEG 61 336 16.52 
20 kDa GPSP4-PEG 61 51 2.47 
a PEG quantified by the method of Sims and Snape, calibrated against the respective maleimide-activated 
PEG reagent. 
b Peptide quantified by the Invitrogen CBQCA amine assay, calibrated against GPRP or GPSP respectively. 
 
 
Interestingly, the CBQCA assay appeared to overestimate the peptide content for 
the GPRPn-PEG conjugates but not the GPSPn-PEG conjugates. Indeed, if the results for 
the GPSPn-PEG conjugates were true, it would imply that we were only able to achieve 
approximately 65% conjugation, instead of the 90% conjugation expected following 
complete reaction of the ~90% substituted maleimide-activated PEG. Due to uncertainty 
in the interpretation for the CBQCA quantitation, the results from the Sims and Snape 
PEG quantitation method were used for the quantitation of conjugates used in this work. 
In doing so, we have assumed that the PEG conjugates were 100% functionalized and 
that the conjugation to GPRPAAC or GPSPAAC was 100% complete. 
4.4. Thrombin Clotting Time and Clot Turbidity 
Fibrin clot structure can be inferred from turbidity profiles of clotting mixtures of 
fibrinogen and thrombin [46]. In general, thicker fibrin bundles are associated with turbid 
clots whereas thinner fibrin bundles result in clear or glassy clots. A clear mixture can 
also be indicative of the absence of fibril assembly and clot formation, such as in the 
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presence of large excess of knob ‘A’ mimics, notably GPRP. The use of real-time 
turbidity measurements of clotting mixtures in conjunction with end-point protein 
measurements allowed a rapid screen of clotting mixtures to identify mixture 
compositions that perturb, but not completely inhibit, the polymerization process. 
4.4.1.  Characterizing Fibrin Clot Formation 
To establish the basic analytical parameters for fibrin clot formation, we assessed 
the clotting characteristics of fibrinogen in the presence of the control materials – 
peptides GPRP and GPSP, and non-functionalized PEG. As expected, the presence of the 
peptide GPRP reduced clot turbidity in a dose-dependent manner (Figure 7A), 
corroborating the early findings of Doolittle et al. [139]. In contrast, our control peptide, 
GPSP, did not significantly impact the turbidity profile of the clotting mixture at the 
corresponding dosages (Figure 7B). Interestingly, the presence of large amounts (100:1 
molar ratio PEG-to-fibrinogen) of 10 kDa PEG amplified the turbidity of the clotting 
mixtures (Figure 7C). We note that early studies by Carr et al. found that dextran T70, 
poloxamer 188 and poloxamer 407 increased fibrin fiber size and clot turbidity [147-149] 
and that PEG may be acting in a similar fashion. 
To further investigate this phenomenon, the initial (solid symbols) and final (open 
symbols) turbidity values of the different mixtures were plotted (Figure 7D), indicating 
that the presence of PEG increased the final absorbance but not the initial absorbance of 
the mixture, despite the 1 h preincubation step prior to the addition of clotting enzymes, 
thrombin and FXIIIa.  
The clotting half-time, defined as the time required for the clot to reach half the 
final turbidity value, was calculated from the clotting curves (Figure 7E). The results 
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indicate that a 100:1 molar excess of GPRP not only reduced the overall turbidity but also 
increased the clotting half-time of the mixture. While PEG significantly increased 
mixture turbidity, it did not have a statistically significant impact on clotting half-time. 
 
 
Figure 7. Fibrin polymerization parameters (using 1 mg/mL fibrinogen, 0.25 NIHU/mL thrombin, 5 
Loewy units/mL FXIIIa) in the presence of GPRP, GPSP and PEG. Representative turbidity profiles 
in the presence of GPRP (A), GPSP (B) and PEG (C) at 1:1, 10:1 and 100:1 peptide/PEG-to-
fibrinogen molar ratios. (D) Plot of absolute initial (solid symbols) turbidity values and final (empty 
symbols) turbidity values from the entire experimental data set (n = 6).  (E) Clotting half-times, 
defined as the time required for the clot to reach half the final turbidity value (at 1 h following 
enzyme addition), calculated from the turbidity curves. (F) The percentage of clottable protein, back-
calculated from the amount of soluble protein in the clot liquor extracted from compressed clots, 
normalized against controls without clotting enzymes. 
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The fibrin clot was then carefully compressed and the concentration of soluble 
protein in the liquid fraction (i.e. clot liquor) was assessed. The amount of clotted protein 
was back-calculated using the respective controls and reported as % clottable protein 
(Figure 7F). As expected, the results indicate that GPRP, but not the control GPSP, 
reduced the % clottable protein of the mixtures. Intriguingly, a 100:1 excess of PEG of 
the mixture had no significant effect on the overall clottability of the mixture despite the 
increased turbidity of the resulting clot. Further experiments carried out with the knob-
PEG conjugates were therefore limited to conjugate-to-fibrinogen molar ratios of 10:1 
and below to minimize any confounding effects arising from higher PEG concentrations. 
4.4.2.  Mixture Clottability and Clotting Half-Time 
The effect of GPRPn-PEG and GPSPn-PEG conjugates on fibrin clot formation 
was assessed at 1:10, 1:1 and 10:1 conjugate-to-fibrinogen molar concentrations. Clots 
were formed at all three dosages for all the conjugates evaluated in this work. However, 
the tenuous clots formed at the highest GPRPn-PEG dosages (open symbols/dashed lines) 
i.e. 10:1, had a comparatively low clottability of 70-80% compared to their respective 
GPSPn-PEG controls (solid symbols/solid lines) with clottability above 90% (Figure 8A, 
B). Moreover, the clotting half-times of these mixtures were significantly longer than the 
controls (Figure 8C, D). At a 1:1 ratio, the clotting half-times for the GPRP2-PEG 
conjugates were not significantly perturbed and the overall turbidity profiles were similar 
in shape to that of the controls [144]. A similar phenomenon was observed for the 2 kDa 
GPRP4-PEG conjugate. In contrast, the profiles for the 10 and 20 kDa GPRP4-PEG 
conjugates were significantly flatter, nearly doubling the apparent clotting half-time. 
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Figure 8. Fibrin polymerization parameters in the presence of knob-PEG conjugates. % Clottable 
protein of hydrogels formed in the presence of GPxP2-PEG (A) and GPxP4-PEG conjugates (B) at 
1:10, 1:1 and 10:1 conjugate-to-fibrinogen molar ratios. Clotting half-times in the presence of GPxP2-
PEG (C) and GPxP4-PEG conjugates (D). Solid symbols and lines correspond to data for the GPSPn-





4.4.3.  Turbidity Measurements 
A closer examination of the turbidity profiles indicate that the final absorbances 
of mixtures at a 10:1 conjugate-to-fibrinogen ratio were consistently lower than the 
controls, possibly indicative of both reduced overall clottability and structural changes 
due to the increased clotting half-time. A notable result was observed at a 1:1 ratio, with 
the 2 kDa GPRP2-PEG conjugate increasing the final turbidity, and the 5 and 7.5 kDa 
GPRP2-PEG conjugates reducing the overall turbidity (Figure 9A). Similarly, the 
presence of the 2, 10 and 20 kDa GPRP4-PEG conjugates at a 1:10 ratio slightly 
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increased the overall absorbance of the mixtures although the opposite phenomenon was 
observed at the 1:1 and 10:1 conjugate-to-fibrinogen ratios (Figure 9B). 
 
 
Figure 9. Turbidity of hydrogels formed in the presence of knob-PEG conjugates. Final turbidity 
values of hydrogels formed in the presence of GPxP2-PEG (A) and GPxP4-PEG conjugates (B) at 
1:10, 1:1 and 10:1 conjugate-to-fibrinogen molar ratios. Initial turbidity values of hydrogels formed 
in the presence of GPxP2-PEG (C) and GPxP4-PEG conjugates (D). Solid symbols and lines 
correspond to data for the GPSPn-PEG control conjugates; empty symbols and dashed lines 




A plot of initial mixture turbidities prior to the addition of clotting enzymes 
showed that the pre-incubation of the GPRPn-PEG conjugates with fibrinogen generally 
had the greatest impact on mixture turbidity at a 1:1 ratio (Figure 9C, D). This trend was 
not observed for the corresponding GPSPn-PEG controls. The increased light scattering at 
this particular ratio is suggestive of fibrinogen assembly arising from knob:hole 
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interactions since each fibrinogen has up to 4 available holes for binding to the 2-arm and 
4-arm conjugates. Further experiments were therefore pursued using a 1:1 conjugate-to-
fibrinogen molar concentration. 
4.5.  FXIIIa-Mediated Crosslinking 
It has been shown that the crosslinking activity of FXIIIa is heavily influenced by 
fibrin assembly and fiber orientation [41, 42, 54]. Since the clot turbidity results suggest 
differences in fibril organization in clotting mixtures, the presence of knob-PEG 
conjugates may consequently alter the crosslinking pattern of the fibrin(ogen) chains 
within the clot.  
4.5.1.  Quantitation of α and γ  Chain Crosslinking 
In general, GPRPn-PEG conjugates appeared to reduce the extent of α chain 
crosslinking compared to their respective GPSPn-PEG controls, particularly in the case of 
the 3.5 kDa GPRP2-PEG and 20 kDa GPRP4-PEG (Figure 10A). In contrast, the extent of 
γ chain crosslinking was not perturbed by the presence of knob-PEG conjugates under the 
clotting conditions used (Figure 10B). The presence of unconjugated peptide (denoted 
GPxP) did not perturb the extent of α and γ chain crosslinking.  
For further clarification of these results, identical experiments were run in the 
absence of thrombin and with a large excess of FXIIIa (50 Loewy units/mL) to 
compensate for its reduced activity in the absence of thrombin. As expected, the results 
indicate that the presence of the GPRPn-PEG conjugates increased the extent of both α 
and γ chain crosslinking, notably in the presence of the 10 kDa GPRP4-PEG conjugate 
(Figure 10C, D). The trend in the % crosslinked chains suggests a size dependency 
wherein the optimum PEG size for promoting FXIIIa crosslinking in the absence of 
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thrombin is around 3.5 kDa for GPRP2-PEG and 10 kDa for GPRP4-PEG. These 
particular conjugates were found to reduce the % α chain crosslinked in the presence of 
thrombin while smaller conjugates such as the 2 kDa GPRP2-PEG and 2 kDa GPRP4-
PEG did not significantly perturb the extent of crosslinking of both α and γ chains.  
 
 
Figure 10. Densitometry analysis of fibrin(ogen) chain species in hydrogels formed in the presence of 
knob-PEG conjugates at a 1:1 conjugate-to-fibrinogen molar ratio. Bands corresponding to α , β , and 
γ  chains on the Coomassie-stained gels were quantified using ImageJ, normalized against the non-
crosslinkable β  chain in each sample, then normalized against the uncrosslinked negative controls 
run on each gel. % crosslinked α  chain (A) and γ  chain (B) in hydrogels formed in the presence of 
both thrombin and FXIIIa. % crosslinked α  chain (C) and γ  chain (D) in hydrogels formed in the 
presence of 50 Loewy units/mL FXIIIa only. Indicated statistical significance calculated from two-






Figure 11. Western blots of solubilized hydrogels formed in the presence of knob-PEG conjugates at 
a 1:1 conjugate-to-fibrinogen molar ratio. The hydrogels formed under the designated conditions 
were run on reducing 7.5% SDS-PAGE gels, transferred onto PVDF membranes and blotted 
sequentially with anti-α  and anti-γ  chain antibodies. (A,B) Blots illustrating the crosslinking pattern 
in the presence of GPxP2-PEG conjugates and both clotting enzymes (0.25 NIH U/mL thrombin, 5 
Loewy units/mL factor XIIIa). (C,D) Blots illustrating the crosslinking pattern in the presence of 
GPxP2-PEG conjugates and factor XIIIa (50 Loewy units/mL) only. (E,F) Blots illustrating the 
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crosslinking pattern in the presence of GPxP4-PEG conjugates and both clotting enzymes. (G,H) 
Blots illustrating the crosslinking pattern in the presence of GPxP4-PEG conjugates and factor XIIIa 
only. Lane assignments are: (*) Biorad Precision Plus Protein All Blue Standards, (a) GPRP, (b) 
GPSP, (c) 2 kDa GPRP2-PEG, (d) 2 kDa GPSP2-PEG, (e) 3.5 kDa GPRP2-PEG, (f) 3.5 kDa GPSP2-
PEG, (g) 5 kDa GPRP2-PEG, (h) 5 kDa GPSP2-PEG, (i) 7.5 kDa GPRP2-PEG, (j) 7.5 kDa GPSP2-
PEG, (k,s) no enzyme controls, (l) positive (no conjugate) control, (m) 2 kDa GPRP4-PEG, (n) 2 kDa 




4.5.2.  Identification of Crosslinked Species 
In attempt to uncover the reason behind the reduced α chain crosslinking in the 
presence of the GPRPn-PEG conjugates, the electrophoresced samples were transferred to 
PVDF membranes and probed sequentially with anti-α and anti-γ chain antibodies. The 
use of both antibodies simultaneously in a multiplexed setup was not considered as we 
expected to observe the presence of α-γ hybrid crosslinked products. Moreover, the anti-α 
chain antibody appeared to be weaker and less specific compared to the anti-γ chain 
antibody, which could also bias the readouts. 
Interestingly, Western blots for the α and γ chains did not suggest any striking 
differences in the crosslinking pattern obtained in the presence of the conjugates as 
compared to the controls (Figure 11).  
4.6.  Network Morphology 
Fibrin networks have been observed using transmission electron microscopy 
(TEM) [25] and scanning electron microscopy (SEM) [46, 47]. While these techniques 
offer excellent resolution down to the nanometer-scale, the sample preparation required 
for EM in general distorts clot structure due to the high water content of these hydrogels. 
Instead, we decided to employ confocal microscopy for the visualization of fluorescently-
labeled fibrin fibers formed in the presence of the knob-PEG conjugates. While the 
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resolution of the confocal microscope is only on the micrometer-scale, the advantages of 
being able to view a hydrated gel on different focal planes (creating a z-stack of images), 
and the ability to view clot formation and degradation in real time has led to increasing 
use of this technique in the field [135, 150]. The structure of the fibrin networks formed 
in the presence the knob-PEG conjugates were also analyzed in relation to their 
rheological properties. 
4.6.1.  Confocal Imaging 
Using 10% labeled fibrinogen with a final fibrinogen concentration of 1 mg/mL, 
network formation was clearly visible under control conditions (Figure 12A). In the 
presence of a 100-molar excess of non-functionalized PEG, where mixture turbidity was 
significantly increased (Figure 7C), the fibers were thicker and more clearly defined as 
compared to the control (Figure 12B). Conversely, at a 10:1 peptide-to-fibrinogen molar 
dosing, a more fine-meshed network was formed in the presence of GPRP (Figure 12C) 
as compared to GPSP (Figure 12D). The noisy background appears to be an artifact 
arising from the higher osmolarity of these mixtures due to the added peptide since all the 
images shown were processed using identical gain settings.  
Focusing on the network structure of clots formed in the presence of an equimolar 
dosing of knob-PEG conjugate, it was noted that clots formed in the presence of the 
GPSPn-PEG conjugates were similar to the control (compare Figure 12A with 6F, H, J, L, 
N, P, R), while very clear conjugate size-dependent trends were observed with the 
GPRPn-PEG conjugates. Notably, the fibers formed in the presence of 2 kDa GPRP2-PEG 
(Figure 12E) and 2 kDa GPRP4-PEG (Figure 12M) appeared to be thicker and straighter. 
The networks formed in the presence of 3.5 kDa and 5 kDa GPRP2-PEG (Figure 12G, I) 
 64 
appeared to resemble their respective GPSP2-PEG controls (Figure 12H, J) the closest, 
but with the inclusion of tight nodules of proteins dispersed throughout the matrix. In the 
presence of the larger GPRPn-PEG conjugates – 7.5 kDa GPRP2-PEG, 10 kDa and 20 
kDa GPRP4-PEG – the networks appeared to comprise ultrathin and highly-branched 
fibers nearing the resolution limits of the microscope (Figure 12K, O, Q). These results 
corroborate the significantly decreased clot turbidities of these mixtures despite their 
maintained clottability as determined by clottable protein measurements. Tight nodules of 
protein continued to be visible in these matrices, but not in their respective controls 




Figure 12. Confocal images of hydrogels. Hydrogels were formed within sealed chambers on glass 
slides and imaged using laser scanning confocal microscopy. Images were rendered from 45×45×10 
µm slices. (A) Control clot (1 mg/mL fibrinogen, 0.25 NIH U/mL thrombin, 5 Loewy units/mL factor 
XIIIa). (B) Representative network structure formed in the presence of 100:1 molar ratio of PEG-to-
fibrinogen. (C) Network structure in the presence of 10:1 molar ratio of GPRP-to-fibrinogen. (D) 
Network structure in the presence of 10:1 molar ratio of GPSP-to-fibrinogen. Subsequent paired 
images are of hydrogels formed in the presence of GPRPn-PEG or GPSPn-PEG conjugates at a 1:1 
conjugate:fibrinogen molar ratio as follows: 2 kDa GPxP2-PEG (E,F), 3.5 kDa GPxP2-PEG (G,H), 5 
kDa GPxP2-PEG (I,J), 7.5 kDa GPxP2-PEG (K,L), 2 kDa GPxP4-PEG (M,N), 10 kDa GPxP4-PEG 
(O,P), 20 kDa GPxP4-PEG (Q,R). 
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4.6.2.  Rheological Characterization 
Utilizing the same clot preparation protocol, the rheological properties of these 
matrices were assessed using a parallel-plate setup in a constant-stress rheometer. The 
results suggest that the presence of the GPRPn-PEG conjugates generally reduces the 
elastic modulus of the clot although the loss tangent, reflecting clot viscosity, was not 
significantly perturbed (Figure 13). Intriguingly, this trend in elastic moduli appears to 
recapitulate the trends seen in % α chain crosslinking (Figure 10A), despite the vast 
differences in network structure observed through confocal imaging (Figure 12), 
suggesting that clot mechanical properties under our experimental conditions is more 
dependent upon α chain crosslinking than network structure. 
 
 
Figure 13. Rheological characterization of hydrogels formed in the presence of knob-PEG conjugates 
at a 1:1 conjugate:fibrinogen molar ratio. Elastic moduli (A) and loss tangents (B) were obtained 
from a sample size of at least n = 6 for each condition. Indicated statistical significance calculated 









4.7.  Plasmin-Mediated Clot Degradation 
Degradation assays were carried out to demonstrate that the clots formed in the 
presence of the knob-PEG conjugates were still susceptible to normal fibrinolysis and 
clot degradation. 
4.7.1.  Clot Degradation 
Clots formed in the presence of GPxPn-PEG conjugates were overlaid with 
plasmin and incubated on a shaker incubator at room temperature. The results suggest 
that all the clots degraded at a constant rate such that the mixture turned clear in 
approximately 9 hours, regardless of the starting turbidity of the clot (Figure 14A,B). For 
a more objective comparison of the degradation rate across the different mixtures, the 
amount of soluble protein in the overlay was assessed. Interestingly, the results indicate 
that the degradation rate of the clots did not vary significantly across the different 
conjugates (Figure 14C,D). Similar results were obtained for clots formed in the presence 
of varying doses of the conjugates (data not shown).  
The rate of exogenous plasmin-induced degradation reflects several parameters, 
including the diffusion of plasmin into the clot and fiber susceptibility to plasmin 
degradation. Altering fibrin network structure via fibrinogen and thrombin concentration, 
early studies have suggested that thin fibers are more resistant to plasmin digestion than 
thick fibers [59, 151]. While it is now generally accepted that clots comprising thin fibers 
are digested faster, it is clear that results from clot degradation assays are notoriously 




Figure 14. Degradation profiles of hydrogels formed in the presence of knob-PEG conjugates at a 1:1 
conjugate-to-fibrinogen molar ratio upon the addition of an equal volume of 0.01 mg/mL (~0.06 
µmol/min/mL) plasmin. Change in turbidity of hydrogels formed in the presence of GPxP2-PEG (A) 
and GPxP4-PEG conjugates (B). Quantitation of soluble protein in the plasmin overlay of hydrogels 
formed in the presence of GPxP2-PEG (C) and GPxP4-PEG conjugates (D). 
 
 
4.8.  Discussion and Conclusions 
Past attempts have been made to alter fibrin matrix properties through the direct 
conjugation of PEG to fibrinogen, followed by UV-induced crosslinking of the 
functionalized PEG moieties, or the addition of thrombin to induce gelation [86, 89, 90].  
In contrast, the objective of the this work was to explore the possibility of altering fibrin 
network architecture through the use of multivalent knob-PEG conjugates that actively 
engage fibrin polymerization holes, potentially facilitating alternative mechanisms of 
polymerization. In this work, we have identified various techniques of analyzing fibrin 
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hydrogels and successfully demonstrated the ability to modulate fibrin network structure 
through the addition of GPRP2-PEG and GPRP4-PEG conjugates. 
By varying the size and valency of the knob-PEG conjugate added to fibrinogen, 
we were able to induce significant changes in fibrin network structure without sacrificing 
the overall clottability of the mixture. In particular, the results indicate that the larger 
conjugates used in this study favored the formation of fine highly branched networks, 
even as fibrinogen, conjugate, thrombin and FXIIIa molar concentrations were kept 
constant. Moreover, the networks formed were stable and did not appear to change 
following an overnight incubation (data not shown). This suggests that larger conjugates 
with long mobile PEG chain linkers between the peptide knobs were interfering with the 
lateral aggregation of the protofibrils to form thick fibers, possibly by non-directional 
orienting of fibrinogen molecules mediated by knob:hole interactions prior to thrombin 
addition. Moreover, the decrease in % α chain crosslinking also suggests that the large 
knob-PEG conjugates are inhibiting the lateral aggregation and alignment that favors this 
type of crosslinks. 
 Intriguingly, these networks are reminiscent of those formed in the presence of 
high thrombin concentrations, where rapid fibrinopeptide removal and formation of 
knob:hole interactions results in a fine-meshed but characteristically weaker clot [47, 
152]. We speculate that the juxtaposition of the crosslinking sites during the 
preincubation of the knob-PEG conjugates with fibrinogen prior to the addition of 
thrombin had an analogous effect. These results would suggest that the design of 
bisbivalent or double-pincer knob-PEG linkers could favor the formation of coarse 
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networks with thick fibers by pinning the ends of the fibrinogen molecule together to 
form protofibril-like structures, even in the absence of clotting enzymes. 
 70 
CHAPTER 5 
TEMPERATURE MODULATION KNOB:HOLE INTERACTIONS 
 
For this chapter, we propose the design of self-assembling mixed protein micelles 
that exhibit temperature-modulated avidities for fibrinogen though knob peptide display. 
Polymers that undergo phase transitions in response to changes in temperature and pH 
have been employed in the creation of a variety of stimuli-responsive conjugates, 
interfaces and nanocarrier systems [153-155]. Given the extensive background research 
conducted on ELPs and the development of several inspiring application-directed systems 
(see section 2.3), we also saw this as an opportunity to employ our expertise in 
recombinant protein engineering to test out some fundamental principles on ELP 
assembly and chain collapse.  
We designed two ELP diblock proteins that should assemble to form a 
temperature-responsive peptide-displaying mixed micelle. These ELP diblock proteins 
share a common C-terminal “core” ELP block (ELPA) but varying N-terminal “outer” 
ELP blocks (ELPB, ELPC), where Tt,A < Tt,B < Tt,C. We hypothesized that the two diblock 
proteins (ELPB-ELPA, ELPC-ELPA) would form mixed micelles upon the collapse of 
ELPA, then exhibit sequential collapse of the outer block, ELPB, then ELPC (Figure 15). 
This sequential collapse should allow the selective display and retraction of the outer end 
of the ELPB block as the mixed micelles are brought above and below Tt,B, without 




Figure 15. Schematic depicting the idealized assembly and collapse of the engineered ELP diblock 
proteins in response to increasing temperature (left to right). ELPA in black, ELPB in red, ELPC in 
blue, where Tt,A < Tt,B < Tt,C. Below Tt,A, both ELPB-ELPA and ELPC-ELPA exist as free protein 
chains. Above Tt,A, the hydrophobic collapse of ELPA results in the self-assembly of mixed micelles 
that display fibrinogen-binding peptides (in yellow). Above Tt,B, the collapse of ELPB results in the 
retraction of fibrinogen-binding peptides and concomitant release of fibrinogen. Above Tt,C, the 




We expressed GPRP (or the control GPSP) sequence on the N-terminus of the 
ELPB-ELPA diblock protein to study the interaction of the knob-displaying mixed 
micelles with fibrinogen at different temperature regimes. We hypothesized that the 
formulated self-assembling peptide-displaying mixed micelles will display GPRP and 
bind to fibrinogen at ambient conditions (below Tt,B), but not at physiological conditions 
(above Tt,B) due to selective outer block collapse. Thus, the expectation is that the GPRP-
displaying mixed micelles will perturb fibrin network formation at ambient temperatures 
but not at physiological temperatures, thus triggering normal clot formation in vivo. 
The results obtained from this project were prepared in a manuscript for 
submission to Biomacromolecules. 
5.1.  Experimental Design 
An ELP library containing the coding sequences for ELPs of different 
composition and lengths was created in order to optimize the transition characteristics of 
the ELP diblock proteins. In particular, these ELP diblock proteins had to form mixed 
micelles within the desired temperature regime (i.e. ambient temperatures).  
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ELP transitioning characteristics were evaluated using a protein aggregation 
assay. The mixed micelles were characterized using light scattering techniques and 
fluorescence resonance energy transfer (FRET). The avidity of these mixed micelles for 
fibrinogen was tested at different temperature regimes using several complementary 
experimental setups. The impact of these mixed micelles on fibrin polymerization 
dynamics was analyzed using turbidity and confocal imaging. 
5.2.  Materials and Methods 
5.2.1. Development of pET15b Expression System  
The entire segment coded between the NcoI and XhoI sites on the Novagen 
pET15b protein expression plasmid vector (Merck, Darmstadt, Germany) was replaced 
by a segment coding for the myc tag, the thrombin cleavage site LVPR↓GPRP (or control 
LVPR↓GPSP), and the SfiI restriction site (for inserting the ELP open reading frame). 
Briefly, the following sequences were ordered as 5’ phosphorylated PAGE-purified 
primers from Invitrogen (Carlsbad, CA):  
 









1 Underlined sequences are sections for the NcoI and XhoI digest overhangs 
2 Sequences in bold code for the GPRP or GPSP peptides at the thrombin cleavage site 
3 Sequences in italics represent the SfiI recognition site for ELP cloning 
 
Mixtures of 2 µM of each primer (combination #1: F1, F2, R1, R2; combination 
#2: F1, F3, R1, R3) were made up in 1X ligation buffer and annealed by ramp cooling 
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from 99oC to 25oC over 60 minutes. The pET15b plasmid was digested with NcoI and 
XhoI, then dephosphorylated using heat-deactivate-able Antarctic phosphatase. The 
restriction digest was run on an agarose gel and the band with the digested plasmid was 
extracted and purified using the QIAquick gel extraction kit (QIAGEN, Valencia, CA). 
The gel-extracted plasmid and the annealed primers were ligated using T4 DNA Ligase 
and transformed into electro-competent XL-1 Blue cells. Selection for successfully 
ligated plasmids containing the insert was made on LB + ampicillin plates. Plasmids were 
extracted from cultures using the QIAquick Spin Miniprep Kit and verified via 
sequencing (Eurofins MWG Operon, Huntsville, AL). These modified pET15b plasmids 
were denoted pET15b-MSfiGPRP, pET15b-MSfiGPSP. 
For plasmid versions coding for a C-terminal cysteine after the SfiI restriction 
site, the annealed primer pair F4 and R4 was inserted into modified pET15b vectors 
generated above. Briefly, the pET15b-MSfiGPRP, pET15b-MSfiGPSP vectors were digested 
sequentially with SfiI and XhoI. The digested plasmids were dephosphorylated then gel-
purified. The gel-extracted plasmids were ligated with the annealed primer set F4+R4 and 
transformed into electro-competent XL-1 Blue cells. Selection for successfully ligated 
plasmids containing the insert was made on LB + ampicillin plates. Plasmids were 
extracted from cultures using the QIAquick Spin Miniprep Kit and verified via 
sequencing. These plasmids were denoted pET15b-MSfiGPRP-C, pET15b-MSfiGPSP-C. 
5.2.2.  Creation of ELP Coding Sequence Library 
3 cloning cassettes were designed to code for 3 different ELPs, namely ELPA [ 
(VPGIG)4VPGVG]60, ELPB [(VPGAG)4VPGVG]80, and ELPC [(VPGPG)4VPGVGGS]40, 
using the technique of recursive directional ligation in pUC19 as described by Meyer and 
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Chilkoti [156]. Briefly, the following sequences were ordered as 5’ phosphorylated 
PAGE-purified primers from Invitrogen:  
 
Name Sequence (5’ to 3’) 
I-F AATT CTC CAC GGC GTG GGT GTT CCG GGC ATT GGT GTC CCA GGT ATC GGC GTA 
CCG GGC ATT GGT GTT CCT GGT ATC GGC GTG CCG GGC TGG CA 
I-R AGC TTG CCA GCC CGG CAC GCC GAT ACC AGG AAC ACC AAT GCC CGG TAC GCC 
GAT ACC TGG GAC ACC AAT GCC CGG AAC ACC CAC GCC GTG GAG 
A-F AATT CTC CAC GGC GTG GGT GTT CCG GGC GCG GGT GTC CCA GGT GCC GGC 
GTA CCG GGC GCA GGT GTT CCT GGT GCT GGC GTG CCG GGC TGG CA 
A-R AGC TTG CCA GCC CGG CAC GCC AGC ACC AGG AAC ACC TGC GCC CGG TAC GCC 
GGC ACC TGG GAC ACC CGC GCC CGG AAC ACC CAC GCC GTG GAG 
P-F AATT CTC CAC GGC GTG GGT GGG TCT GTT CCT GGC CCG GGT GTC CCA GGT CCG 
GGC GTA CCT GGC CCG GGT GTT CCA GGT CCG GGC GTG CCG GGC TGG CA 
P-R AGC TTG CCA GCC CGG CAC GCC CGG ACC TGG AAC ACC CGG GCC AGG TAC GCC 
CGG ACC TGG GAC ACC CGG GCC AGG AAC AGA CCC ACC CAC GCC GTG GAG 
 
Mixtures of 2 µM for each primer pair were made up in 1X ligation buffer and 
annealed in a PCR machine by ramp cooling from 99oC to 25oC over 60 minutes. The 
pUC19 plasmid was digested with EcoRI and HindIII, then dephosphorylated. The gel-
extracted plasmids and the annealed primers were ligated and transformed into XL-1 
Blue cells. Selection for successfully ligated plasmids containing the insert was made on 
LB + ampicillin plates. Plasmids were extracted from cultures and verified via 
sequencing. 
In the process of recursive directional ligation, the “host” plasmid was digested 
with PflMI, then dephosphorylated. The “insert” plasmid was digested with PflMI and 
BglI, then run on a gel to separate the insert from the plasmid fragments. The band 
containing the insert was extracted and purified. The gel-extracted host plasmid and 
insert were ligated and transformed into electro-competent XL-1 Blue cells. Selection for 
successfully ligated plasmids containing the added insert was made on LB + ampicillin 
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plates. Plasmids were extracted from cultures and verified via sequencing. This process 
was repeated until the desired number of repeats in the desired order was attained. 
5.2.3.  Insertion of ELP Coding Sequences into pET15b-MSfi Vectors 
The SfiI site in the multiple cloning site (MCS) was used to insert the ELP open 
reading frame into the pET15b-MSfiGPRP, pET15b-MSfiGPSP, pET15b-MSfiGPRP-C, 
pET15b-MSfiGPSP-C vectors obtained in section A.1 above using standard molecular 
cloning techniques. Briefly, the host pET15b-MSfiGPxP(-C) plasmid was digested with 
SfiI, then dephosphorylated. The insert-containing pUC19 plasmid was digested with 
PflMI and BglI, then run on a gel to separate the desired insert from the host plasmid 
fragments. The band containing the insert was extracted and purified. The gel-extracted 
host plasmid and insert were ligated and transformed into electro-competent XL-1 Blue 
cells. Selection for successfully ligated plasmids containing the insert was made on LB + 
ampicillin plates. Plasmids were extracted from cultures and verified via sequencing. The 
plasmids generated were denoted pET15b-MSfiGPRP-ELPB-ELPA, pET15b-MSfiGPSP-
ELPB-ELPA, pET15b-MSfiGPRP-ELPB-ELPA-C, pET15b-MSfiGPSP-ELPB-ELPA-C, 
pET15b-MSfiGPRP-ELPC-ELPA, pET15b-MSfiGPSP-ELPC-ELPA, pET15b-MSfiGPRP-ELPC-
ELPA-C, pET15b-MSfiGPSP-ELPC-ELPA-C. 
5.2.4. Protein Production and Purification of ELP Diblock Fusions 
pET15-MSfiGPxP(-C) plasmids containing the desired ELP inserts were 
transformed into electro-competent BL21(DE3) E. coli. Protein production of the myc-
tagged proteins was induced by the addition of 1 mM IPTG (final) when the culture 
reached OD600 0.6-0.8. 4 hours following IPTG addition, cells were pelleted by 
centrifugation at 4oC and resuspended in ice-cold PBS. The lysate was sonicated at 
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maximum power (without protein foaming) for 10s ON/20s OFF for a total of 90s 
processing time. The cell debris was removed by centrifugation at 15000×g, 15 min, 4oC. 
0.5% polyethyleneimine (final) was added to precipitate out the DNA in the lysate before 
re-centrifugation.  
The cleared lysate was subject to inverse transition cycling (ITC) as described in 
Meyer et al.[105] Briefly, the lysate was warmed to room temperature before the gradual 
addition of 5 M NaCl until the ELP begun to precipitate (typically at about 1 M to 2.5 M 
total NaCl depending on the ELP identity). The mixture was centrifuged at 10000×g, 15 
min, 30oC to separate the ELP precipitate from the soluble bacterial proteins remaining in 
the supernatant, which was discarded. The ELP pellet was resolubilized in cold PBS and 
centrifuged at 10000×g 15 min, 4oC to separate the soluble ELP from the insoluble 
bacterial proteins. The ELP-containing solution was transferred to a fresh tube and the 
pellet was discarded. This process was repeated.   
The semi-purified ELP was then incubated overnight with bovine thrombin dosed 
at 10 U per mg recombinant protein. The process of ITC was then repeated at least 
another 4 times to purify the cleaved ELP from the thrombin and myc tag, and any 
remaining bacterial proteins. ELP purity was verified using SDS-PAGE. Western blot 
using a mouse monoclonal anti-myc antibody (Invitrogen) and IRDye 800 goat anti-
mouse IgG (LI-COR) was used to verify complete removal of the myc tag from the ELP 
fusions. Electrospray ionization mass spectrometry (ESI-MS) performed by the Georgia 
Institute of Technology Bioanalytical Mass Spectrometry Facility using the Micromass 
Quattro LC was used to confirm protein size. 
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The protein solutions were quantified using the Quant-iT protein assay kit 
(Invitrogen), then aliquoted and stored at -80°C until use. Note: Instances of “GPRP-
ELPB-ELPA mix” and “GPSP-ELPB-ELPA mix” used in this paper refer to 1:4 mixtures 
of one part of GPRP-ELPB-ELPA or GPRP-ELPB-ELPA, with four parts of GPSP-ELPC-
ELPA respectively. In other words, 2 µM of GP(R/S)P-ELPB-ELPA and 8 µM of GPSP-
ELPC-ELPA for a 10 µM ELP solution. 
5.2.5.  ELP Transition Characterization 
Temperature-dependent transitions of the ELP diblock proteins were monitored 
using a protein-binding fluorescent dye, SYPRO Orange (Invitrogen #S6650). Following 
a methodology analogous to that reported by Niesen et al. [157], 5× SYPRO Orange 
(final concentration) was added to 96-well optical PCR plates containing varying 
concentrations of the ELP in TBS+Ca (25 mM Tris-HCl pH 7.4, 137 mM NaCl, 5 mM 
CaCl2). The PCR plate was sealed with optical adhesive film and placed into the ABI 
StepOnePlus real-time PCR system (Life Technologies, Carlsbad, CA). Samples were 
heated at 0.9°C/min from 10°C to 65°C and the raw data from the ROX channel was used 
for analysis.  
5.2.6.  Cloud Point Measurements 
The cloud point of 10 µM protein solutions was sampled using the cloud point 
protocol built into the FP900 thermo system for the FP81HT MBC temperature chamber 
(Mettler-Toledo, Columbus, OH). Solutions were loaded into the recommended melting 
point capillaries and inserted into the chamber pre-equilibrated at 25°C. A 1°C/min ramp 
was used and the solution cloud points were evaluated using the default criteria (i.e. a 4% 
transmittance drop of the initial value). 
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5.2.7.  Micelle Characterization via Light Scattering 
Particle characteristics of solutions containing the ELP diblock proteins were 
analyzed using dynamic light scattering (DLS) or photon correlation spectroscopy. 
Briefly, solutions of the ELP diblock were prepared on ice and transferred to a black 
clear-bottom 384-well plate. The plate was spun down at 3000 g, 10 min, 4°C to 
eliminate air bubbles before placing in the DynaPro plate reader (Wyatt, Santa Barbara, 
CA). Following a 15-min thermal equilibration step at 25°C, 20 reads of 20 s acquisitions 
were recorded for each well. This process was repeated at increments of 1°C or 2°C 
(where indicated) until particle aggregation led to heterogeneous micron-sized particles 
generating poor correlation data. Data was collected for at least 4 independently prepared 
runs. For statistical analysis, data from 9 runs were used. Where indicated, 10 µM of 
fibrinogen fragment D was added to wells containing 10 µM ELP diblock proteins. The 
purification of fragment D from a plasmin digest of fibrinogen has been described 
previously [135]. 
5.2.8.  Mixed Micelle Formation via FRET 
ELP diblock proteins with C-terminal cysteines were labeled with either the 
Alexa Fluor 488 or Alexa Fluor 546 (Invitrogen) via sulfhydryl-maleimide chemistry 
following the manufacturer’s recommended protocol. Combinations of AF488-labeled, 
AF546-labeled and unlabeled ELP diblock proteins were added to black clear-bottom 
384-well plates for a total concentration of 1 µM ELP protein per well (higher 
concentrations of labeled protein saturated the fluorescence detectors). The 384-well 
plate was sealed with optical adhesive film and incubated in the H4 Synergy microplate 
reader (Biotek, Winooski, VT) at 25°C for 15 minutes before excitation at 470 nm and 
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acquiring the emission spectrum from 500 to 700 nm using a 2 nm step size. The 
emission spectra were monitored at successive 5°C intervals (30, 35, 40, 45, 50, 55, 
60°C) with a 15-minute incubation time allowed for thermal equilibration with each 
stepwise increase. Changes in the emission peaks were normalized against respective 
control wells containing only AF488-labeled or AF546-labeled protein and designated as 
fold change in emission (Fa = Ema/Ema,control; Fd = Emd/Emd,control). 
5.2.9.  Solid-Phase Fibrinogen Binding Assays 
An enzyme-linked immunosorbent assay (ELISA) was used to establish the 
affinity of fibrinogen for ELP diblock protein covalently immobilized on maleimide-
activated plates via their C-terminal cysteines as described previously [135]. Due to the 
sensitivity of ELP transition characteristics to the Hofmeister effect [158], all assays were 
conducted in a Tris-based buffer (TBS+Ca) in place of the phosphate buffer 
recommended in the manufacturer’s protocol. Briefly, varying concentrations of 
sulfhydryl-containing protein/peptides were conjugated to pre-blocked maleimide-
activated plates (Pierce, Thermo Scientific, Rockford, IL), which were then quenched 
with cysteine. ELP-coated wells were incubated with fibrinogen (#FIB3, Enzyme 
Research Laboratories, South Bend, IN) and the remaining bound fibrinogen after 
washing was detected using HRP-conjugated goat anti-fibrinogen antibody (MP 
Biomedicals #55239) and 1-Step Ultra TMB-ELISA (Pierce) with 1 M H2SO4 as the stop 
solution. All intervening wash steps were conducted in TBS+Ca + 0.5% Tween-20. 
Results were normalized to GPSPFPAC-coated wells (0%) and GPRPFPAC-coated wells 
(100%). 
5.2.10.  Solid-Phase Mixed Micelle Binding Assays 
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A plate-based assay conceptually similar to an ELISA was used to establish the 
affinity of ELP mixed micelles for immobilized fibrinogen on black 96-well plates. 
Briefly, fibrinogen was passively adsorbed on 96-well plates at 0.1 mg/mL for 3 h at 
room temperature. The plates were washed, then blocked with 1% BSA for 1 h at room 
temperature. The wells were washed with pre-warmed buffer before pre-equilibrated 
mixed ELP micelles comprising 2 µM unlabeled ELP (the “functional component”) and 8 
µM labeled GPSP-ELPC-ELPA-AF546 (non-fibrinogen binding component) were added 
to the fibrinogen-coated wells. The plates were incubated at the desired temperatures for 
1 h, washed with pre-warmed TBS+Ca to remove the unbound protein, then allowed to 
equilibrate to room temperature before fluorescence measurements (Ex540nm/Em573nm) 
were taken. Background fluorescence, evaluated from control BSA-coated wells, was 
subtracted from the data, with the result reported as relative fluorescence units. 
5.2.11.  Solution-Phase Turbidity Assays  
A plate-based assay was used to establish the affinity of ELP micelles for 
fibrinogen in solution in clear 384-well plates. ELP mixtures and fibrinogen were 
equilibrated to the desired temperatures before addition to the wells. The plate was 
incubated at the desired temperature for 1 h before turbidity measurements (Abs350nm) 
were taken in the pre-heated plate reader. Background absorbance, evaluated from 
control wells without fibrinogen was subtracted from the data, with the result reported as 
relative turbidity.  
5.2.12.  Turbidity Measurements in the Presence of Thrombin 
Enzyme-catalyzed polymerization of mixtures of fibrinogen and mixed micelles 
was initiated in clear 96-well plates. Briefly, 10 µL of the mixed micelle (20 µM 
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functional component and 80 µM of GPSP-ELPC-ELPA) and 80 µL of 2.5 µM human 
fibrinogen was pre-incubated at the desired temperature for 1 h. Following, 10 µL of 2.5 
NIHU/mL human α-thrombin and 100 Loewy units/mL human FXIIIa (both from 
Enzyme Research Laboratories) were added to the fibrinogen mixture to initiate 
polymerization. The turbidity (Abs350nm) of the mixtures was followed using a plate 
reader. To determine the amount of unclotted protein, the clot was compressed and the 
isolated clot liquor was analyzed for the soluble protein content through absorbance 
measurements (Abs280nm) using the Nanodrop 1000 (Thermo Scientific, Wilmington, 
DE).  
5.2.13.  Confocal Imaging 
Confocal imaging of clots was conducted following the procedure described in 
section 4.2.5. Briefly, fibrin clots containing 10% Alexa Fluor 555-labeled fibrinogen 
were prepared as described above (section 5.2.12) on pre-warmed glass slides on a heat 
block. The slides were sealed and incubated at the desired temperatures for an hour 
before moving to room temperature for imaging on the confocal microscope. 
5.2.14.  Statistical Analysis 
All data was acquired from at least 3 sets of triplicate experiments, and presented 
as mean ± SD unless otherwise stated. Two-tailed t-tests were used to evaluate statistical 
significance (p < 0.05) where indicated. 
5.3.  Knob-ELP Preparation 
The coding sequences for the ELP diblock proteins were successfully created and 
amplified using the pUC19 plasmid. These coding sequences were inserted into the 
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modified pET15b vectors, and then transformed into E. coli BL21(DE3) for IPTG-
induced protein expression under control of the T7 promoter (Figure 16A). The myc-
tagged proteins were purified from the bacterial host proteins via ITC, cleaved with 
thrombin to expose the desired N-terminal peptide sequence, then re-purified via ITC to 
remove the cleaved myc tag and thrombin (Figure 16B).  
Of special note, earlier versions of ELP diblock proteins employing the 6xHis tag 
instead of the myc tag resulted in issues with thrombin cleavage or problems with the 
separation of the cleaved 6xHis tag from the ELP using ITC. The dot blots done on these 
samples indicated the persistent presence of the 6xHis tag even after multiple rounds of 
ITC (data not shown). Trabbic-Carlson et al. had previously shown successful thrombin-
mediated cleavage and removal of ELPs from its fusion partner [106], suggesting that 
thrombin cleavage efficiency is not affected by the adjoining ELP in such protein fusions. 
However, the authors also noted that the ELPs had the propensity to associate with 
hydrophobic proteins even after their cleavage by thrombin [106]. Thus, the decision was 
made to switch to the highly charged and more hydrophilic myc tag for the production of 
our knob-ELP diblock proteins. 
The following proteins were successfully produced: GPRP-ELPB-ELPA, GPSP-
ELPB-ELPA, GPRP-ELPC-ELPA, GPSP-ELPC-ELPA. The same set of proteins containing 
an additional C-terminal cysteine for conjugation of the sulfhydryl to maleimide-





Figure 16. ELP diblock protein design and production. (A) The host pET15b vector was modified to 
code for the desired N-terminal fibrin binding sequences (GPRP, GPSP) at the thrombin cleavage 
site and an optional C-terminal cysteine, with an intervening SfiI restriction enzyme site for the 
insertion of the ELP open reading frame. The open reading frames of the desired ELP blocks (ELPB-
ELPA, ELPC-ELPA) created in the pUC19 plasmid were inserted into the modified pET15b vectors, 
which were then transformed into E. coli BL21(DE3) for protein expression. Further details may be 
found in the indicated sections given on the arrows. (B) Representative SDS-PAGE images (left: 
Coomassie stained gel; right: corresponding Western blot with myc-tag antibody) for GPSP-ELPC-
ELPA (expected size 43949 Da. ELPs are known to run ~20% larger than expected on SDS-PAGE 
gels [156]) demonstrating the purity of the purified ELP diblock protein. Lane assignments: 1 – cell 
lysate; 2 – pre-cleaved ELP diblock protein; 3 – thrombin-cleaved ELP diblock protein. (C) 
Deconvoluted ESI-MS spectrum for myc-tagged GPSP-ELPC-ELPA (expected size 46194 Da; 
dominant peak on the spectrum shown at 46073 Da) demonstrating the purity and identity of the 
protein. Attempts to use ESI and MALDI mass spectrometry for the cleaved and purified ELP 
diblock proteins without the myc tag proved to be unsuccessful, likely due to the lack of charges on 
the purified protein. 
 
 
5.4.  Transition Temperature Characterization 
The transition temperature of ELPs has traditionally been conducted using cloud 
point measurements upon a temperature ramp of typically 1°C/min [96, 100]. Due to 
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instrumental limitations, we employed the use of the SYPRO Orange assay to evaluate 
the phase transitioning behavior of the ELP diblock proteins with temperature ramping in 
a real-time-PCR machine.  
5.4.1.  SYPRO Orange 
The SYPRO Orange thermal stability assay was used to evaluate the phase 
transitioning behavior of the ELP diblock proteins with temperature ramping. SYPRO 
Orange is an environment-sensitive dye that is gaining widespread use in high throughput 
thermal stability or protein aggregation assays due to its high signal-to-noise ratio [159]. 
Transition temperatures of ELP protein solutions could be identified by a rapid increase 
in fluorescence output, corresponding to a peak in the first derivative (Figure 17A,B). 
The results indicate the presence of two transitioning points for all the ELPs, 
including mixtures of different ELP diblocks. The close proximity of the first transition 
temperature, Tt1, for all the solutions at a given ELP concentration (Figure 17C) strongly 
suggests that this transition is associated with the collapse of the common core ELPA 
block, or the self-assembly of ELP diblocks to form micelles. The second transition 
temperature, Tt2, identified was dependent on the identity and relative proportion of the 
variant outer ELP block, ELPB or ELPC, in the protein solution (Figure 17D), suggesting 
that this temperature is associated with the transition of the outer shell. This may reflect 
micelle aggregation as the micelle shell collapsed, or overall destabilization of micellar 
structure to form growing ELP aggregates.  
The intermediate Tt2 identified for mixtures of GP(R/S)P-ELPB-ELPA and GPSP-
ELPC-ELPA, instead of three transition points corresponding to Tt,A, Tt,B and Tt,C, is 
highly suggestive of the formation of mixed micelles comprising both species within a 
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single assembly. In other words, the formation of distinct micelle populations of 
GP(R/S)P-ELPB-ELPA and GPSP-ELPC-ELPA would have resulted in three transition 
temperatures as the GP(R/S)P-ELPB-ELPA micelles aggregated ahead of the GPSP-
ELPC-ELPA micelles as the temperature was ramped up. Since this was not observed, the 
different ELP diblock proteins likely formed mixed assemblies upon the collapse of the 




Figure 17. Temperature transition characteristics evaluated using SYPRO Orange. (A) 
Representative fluorescence readouts from 10 µM solutions of GPRP-ELPB-ELPA, GPSP-ELPC-
ELPA and a 1:4 mixture of GPRP-ELPB-ELPA-to-GPSP-ELPC-ELPA upon a 0.9°C/min temperature 
ramp. (B) The calculated derivatives of the fluorescence curves used to obtain the transition 
temperatures of the solutions. Two distinct transition temperatures (Tt1, Tt2) were observed for all 
solutions within the concentration range tested. (C) Plot of Tt1 as a function of total ELP 
concentration showing a good overlap of the data points from the different solutions tested. (D) Plot 
of Tt2 as a function of total ELP concentration showing dependence of this transition on mixture 









5.5.  Micelle Characterization 
Dynamic light scattering (DLS) was used to evaluate the hydrodynamic radius 
(RH) of the micelles. Supporting multi-angle laser light scattering (MALLS) was also 
conducted by Smith for evaluation of the molecular weight (hence micelle coordination 
number) and radius of gyration (RG) of the micelles (manuscript in preparation). The 
formation of mixed micelles was confirmed by the use of FRET. 
5.5.1.  Micelle DLS Data 
Figure 18A,B suggests that the ELP diblock proteins form largely monodisperse 
(polydispersity < 15%) populations of ~50 nm diameter particles. This is consistent with 
previously reported data using diblock proteins of comparable molecular weight and 
composition [121]. Notably, the RH of GP(R/S)P-ELPB-ELPA is approximately 3 nm 
larger than GP(R/S)P-ELPC-ELPA, likely due to the slightly longer length of the 
GP(R/S)P-ELPB-ELPA chain (comprising 140 pentapeptide repeats) compared to the 
GP(R/S)P-ELPC-ELPA chain (100 repeats). The RH of 1:4 mixtures of GP(R/S)P-ELPB-
ELPA-to-GPSP-ELPC-ELPA appears to approximate that of GP(R/S)P-ELPB-ELPA, an 
expected result if the two diblock proteins came together to form mixed micelles. 
Moreover, the formation of separate populations of distinctly sized GP(R/S)P-ELPB-
ELPA and GPSP-ELPC-ELPA micelles would be expected to increase particle population 




Figure 18. Light scattering data of micelles. (A) Hydrodynamic radius (RH) of 10 µM protein 
solutions calculated using the regularization fit provided by the Dynamics software. (B) 
Corresponding % polydispersity. Data reported as mean ±  SD from the averaged data obtained from 
4 separate runs. (C) Cloud point of 10 µM protein solutions acquired from the Mettler Toledo cloud 




5.5.2.  Cloud Point Measurements 
Results from the SYPRO Orange assay suggested a second transition point (Tt2) at 
about 40, 55 and 50°C for 10 µM solutions of GP(R/S)P-ELPB-ELPA, GP(R/S)P-ELPC-
ELPA, and GP(R/S)P-ELPB-ELPA mixes respectively. This approximates the 
temperatures at which the amplitude of the DLS autocorrelation functions dropped 
drastically and appears to be associated with the formation of polydisperse micron-sized 
aggregates. Evaluation of the solutions using a cloud point measuring cell also suggests 
that Tt2 is associated with the cloud point of the solutions (Figure 18C). 
5.5.3.  FRET 
The functionality of this self-assembling peptide-displaying micelle system relies 
on the formation of mixed micelles by ELP diblock proteins sharing a common core 
ELPA block. The C-terminal sulfhydryl of cysteine-containing ELP diblock proteins was 
conjugated to either AF488 or AF546 fluorophores. Given the Förster radius of 6.31 nm 
for this FRET pair and the ~50 nm diameter of the micelles, a positive FRET signal 
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would be strongly suggestive of colocalization of the C-terminal ELPA blocks within the 
same micelle core.  
As expected, FRET, indicated by a reduction in AF488 emission (Emd) and 
concomitant increase in AF546 emission (Emd), was not significant in mixtures at 
ambient temperatures (Figure 19A), but was observed as temperature increased above Tt1 
(~28.5°C from Figure 17C). The emission spectra of control wells containing either the 
respective AF488-labeled or AF546-labeled proteins did not change appreciably with 
temperature (data not shown). Quantifying this change as Fa/Fd, FRET increased from 
25°C to 35°C, then stabilized at about 2.4 for all the mixtures tested (Figure 19B). 
Interestingly, Fa/Fd for the GPRP-ELPB-ELPA-AF488 with GPRP-ELPB-ELPA-AF546 
positive control showed a slight upward trend past 40°C, which may suggest a 
reorganization of micellar core structure past Tt2 of the protein solution (~40.5°C from 
Figure 17D). Nonetheless, the close proximity of the results from all three mixtures 
suggests that both fluorophores were colocalized within the micelle core, regardless of 





Figure 19. Formation of mixed micelles demonstrated using FRET. (A) Representative emission 
spectrum obtained from an equimolar mixture of GPRP-ELPB-ELPA-AF488 and GPSP-ELPC-ELPA-
AF546 (10% labeled protein of a 10 µM protein solution) excited at 470 nm at various temperatures. 
Emission peaks of donor AF488 (Emd) and acceptor AF546 (Ema) are indicated by arrows. (B) 
Results are reported as fold change in Ema (Fa) over fold change in Emd (Fd) for equimolar mixtures 
of GPRP-ELPB-ELPA-AF488 and GPRP-ELPB-ELPA-AF546 (red), GPSP-ELPC-ELPA-AF488 and 
GPSP-ELPC-ELPA-AF546 (blue), GPRP-ELPB-ELPA-AF488 and GPSP-ELPC-ELPA-AF546 (green) 




5.6.  Interaction of Mixed Micelles with Fibrinogen 
In keeping with the main theme of the document, we are interested in evaluating 
the affinity between the mixed micelles and fibrinogen. First, we demonstrated that the 
binding of the ELP diblock proteins to fibrinogen was stable and specific at all the 
temperature regimes were interested in. We then proceeded to evaluate the interaction of 
the assembled mixed micelles with fibrinogen using both solid-phase and solution-phase 
techniques. 
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5.6.1. Binding Specificity of ELP Diblock Proteins 
The binding of fibrinogen to immobilized ELP diblock proteins was evaluated 
using a standard plate-based ELISA format. As expected, the results indicate that 
fibrinogen bound specifically to GPRP-ELPB-ELPA-C and GPRP-ELPC-ELPA-C but not 
their respective GPSP-displaying controls (Figure 20A). This assay demonstrates the 
specificity of the GPRP:fibrinogen interaction, validates the use of the GPSP control 
tetrapeptide sequence, and also indicates the absence of non-specific interactions between 
the ELP chains and fibrinogen. Interestingly, more fibrinogen bound to saturated GPRP-
displaying ELP-coated wells than saturated GPRP-displaying peptide-coated wells (% 
normalized signal > 100), possibly indicative of steric hindrance when binding to GPRP 
presented in close proximity to the surfaces of the well.  
The binding specificity of the displayed GPRP, versus the control GPSP peptide 
at elevated temperatures was also verified (Figure 20B-D). The experimental protocol 
was unchanged, except for the use of pre-warmed buffers following cysteine quenching 
and incubation of the ELISA plates in a pre-heated incubator. For consistency, TMB 
incubation was still conducted at room temperature for the same development time before 
addition of the stop solution. The raw data (not shown) indicated that the amount of 
soluble fibrinogen bound to control GPRPFPAC-coated wells remained approximately 
constant at the additional temperatures tested (i.e. 32°C, 37°C, 42°C), suggesting that the 
integrity of the knob:hole interactions was conserved at these conditions. Control 




Figure 20. Binding specificity of ELP diblock proteins at elevated temperatures as function of ELP 
coating concentration. In addition to the results obtained at room temperature (A), ELISA was also 
conducted at 32°C (B), 37°C (C) and 42°C (D). The data was normalized to control GPSPFPAC-
coated wells (0%) and GPRPFPAC-coated wells (100%) at each temperature and presented as % 
normalized signal. Solid square symbols – GPRP-ELPB-ELPA, open square symbols – GPSP-ELPB-
ELPA, solid circle symbols – GPRP-ELPC-ELPA, open circle symbols – GPSP-ELPC-ELPA. The 
connecting lines are simply to guide the eye. The data is also presented together as % normalized 




The results suggest that the amount of soluble fibrinogen bound to immobilized 
GPRP-displaying ELP diblock proteins was highest at 22°C and is not significantly 
different at 32°C and 37°C (Figure 20E-F). However, binding between the GPRP-
displaying ELP diblock proteins and fibrinogen appears to drop at 42°C, suggesting that 
temperature-induced conformational changes in the ELP blocks may be interfering with 
binding. Interestingly, the ELISA curves for GPRP-ELPB-ELPA and GPRP-ELPC-ELPA 
were not significantly different at all the temperatures tested, suggesting that changes in 
the common ELPA block may be behind binding affinity modulation. Binding to 
immobilized GPSP-displaying ELP diblock proteins was negligible at all conditions, 
again affirming the specificity of the interaction between GPRP and fibrinogen. 
 92 
5.6.2. Binding Specificity of Mixed Micelles 
The binding of mixed micelles to immobilized fibrinogen was evaluated using a 
plate-based format similar to an ELISA. This assay was specifically designed to monitor 
the binding of mixed micelles, not just (possibly) monomeric ELP diblock proteins, to 
immobilized fibrinogen. Rather than label all the ELP diblock proteins, only the non-
fibrinogen binding GPSP-ELPC-ELPA was labeled with AF546. This labeled protein was 
mixed with the unlabeled “functional component” of the mixed micelle that would be 
expected to bind to fibrinogen (i.e. GPRP-ELPB-ELPA or GPRP-ELPC-ELPA). Any 
GPSP-ELPC-ELPA-AF546 associated with the immobilized fibrinogen is interpreted as 
have been retained in the wells as part of a mixed micelle with the unlabeled functional 




Figure 21. Temperature-responsive binding of mixed micelles to immobilized fibrinogen at 22°C, 
32°C, 42°C. (A) Schematic illustrating binding of fluorescently labeled GPSP-ELPC-ELPA-AF546 (in 
blue) to fibrinogen-adsorbed surfaces as part of a mixed micelle with the unlabeled “functional 
component” GPRP-ELPB-ELPA (in red) below Tt,B. (B) Fluorescence readouts reflecting the amount 
of GPSP-ELPC-ELPA-AF546 recruited to the immobilized fibrinogen by the indicated unlabeled 






As expected, no significant fluorescence was observed at 22°C, where the ELP 
diblock proteins were expected to exist as monomers (Figure 21B). At 32°C, where 
micelle formation was verified, fluorescence was observed in the presence of GPRP-
ELPB-ELPA and GPRP-ELPC-ELPA but not the GPSP controls. This indicates that the 
unlabeled functional component was successful in retaining the labeled non-fibrinogen-
binding GPSP-ELPC-ELPA-AF546 within the wells, likely as part of a mixed micelle. 
Interestingly, at 42°C, an increased fluorescence signal was observed in the presence of 
both GPRP-ELPB-ELPA and GPRP-ELPC-ELPA. Due to the collapse of the ELPB block at 
this temperature (T > Tt,B), we expected to observe less binding in the presence of GPRP-
ELPB-ELPA compared to GPRP-ELPC-ELPA. However, it is noted that only ~1% of the 
originally added labeled protein was retained within the wells, which would have resulted 
in a drastic change in the effective protein concentration within the wells during the 
buffer washes. Since Tt is a function of concentration, this unexpected finding may be an 
experimental artifact. Nonetheless, these results clearly demonstrate the binding 
specificity of the GPRP-displaying ELP diblock proteins (versus the GPSP controls) at all 
3 temperatures of interest, and also the formation of mixed micelles that are capable of 
interacting with fibrinogen. 
5.6.3. Interaction of Mixed Micelles with Soluble Fibrinogen using Turbidity 
As both the GPRP-displaying micelles and hole-containing fibrinogen are 
multivalent entities, we expect to see network formation and an increase in mixture 
turbidity as these components interact with each other (Figure 22A). This unique 
phenomenon was presented in the previous chapter where the addition of equimolar 
 94 
amounts of multivalent GPRP-displaying PEG conjugates to fibrinogen was shown to 




Figure 22. Temperature-responsive binding between micelles and fibrinogen in solution at 22°C, 
32°C, 42°C. (A) Schematic illustrating interaction of mixed micelles with fibrinogen below Tt,B. (B,C) 
Absorbance readouts reflecting the interaction of the pure micelles (comprising the indicated ELP 
diblock proteins only) or mixed micelles (1:4 mixtures of the indicated functional component with 
GPSP-ELPC-ELPA) with fibrinogen are reported as relative turbidity. Asterisks indicate wells in 




As expected, there were no significant changes in mixture turbidity observed at 
22°C, suggesting that the monomeric ELP diblock proteins at this temperature did not 
form a network with fibrinogen (Figure 22). At 32°C, there was a significant increase in 
mixture turbidity in the presence of 10 µM GPRP-ELPB-ELPA and GPRP-ELPC-ELPA 
(Figure 22B), suggesting that micelle formation at this temperature, coupled with 
engagement of fibrinogen holes by the displayed GPRP, led to network formation. At 
42°C, solutions of GPRP-ELPB-ELPA and GPSP-ELPB-ELPA were already past their 
cloud point, invalidating any data obtained from these wells (indicated by asterisks on the 
graph). However, mixtures of GPRP-ELPC-ELPA and fibrinogen exhibited turbidities 
comparable to those 32°C, suggesting that fibrinogen remained engaged with these 
micelles at elevated temperatures. 
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Similar results were obtained in the presence of mixed micelles, wherein no 
significant changes in mixture turbidity was observed at 22°C, while an increase in 
turbidity was observed at 32°C due to the micelle formation (Figure 22C). However, 
mixtures in the presence of mixed micelles exhibit reduced mixture turbidities at elevated 
temperatures (42°C), which may suggest reduced interaction with fibrinogen at these 
temperatures.  These results are congruent with our initial conceptual design where 
retraction of GPRP at elevated temperatures (T > Tt,B) should result in a non-fibrinogen-
binding mixed micelle. Interestingly, the relative turbidity in the presence of GPRP-
ELPC-ELPA mixed micelles was reduced as well. Theoretically, there should not be 
changes in GPRP presentation for this mixed micelle since the ELPC-ELPA section is 
common to both the functional GPRP-ELPC-ELPA component and inactive GPSP-ELPC-
ELPA component. 
5.6.4.  Micelle DLS Data in the Presence of Fibrinogen Fragment D 
For a more direct evaluation of the interaction between the GPRP-displaying 
mixed micelles and fibrinogen holes in real time, DLS was used to detect the changes in 
RH as fibrinogen binds to the micelle. To avoid network formation and aggregation due to 
the multivalency of fibrinogen, fibrinogen fragment D comprising a single (instead of 
paired) set of holes was used.  
A statistically significant change in RH was observed for 10 µM GPRP-ELPB-
ELPA, compared to the control GPSP-ELPB-ELPA, in the presence of 10 µM fragment D 
until particle aggregation (Figure 23A). A similar trend was observed for GPRP-ELPC-
ELPA against the control GPSP-ELPC-ELPA although the RH of the micelles exhibited a 
general decrease in response to temperature (Figure 23B). The moderate increase in RH 
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past ~43°C is probably associated with the denaturation of fibrinogen at these 




Figure 23. Characterization of interaction of mixed micelles with fibrinogen fragment D in response 
to a temperature ramp via dynamic light scattering. RH is reported for pure micelles (A, B) and 
mixed micelles (C, D) in the presence (symbols) and absence (lines) of fibrinogen fragment D. 
Standard deviations for data points in the absence of fragment D are not shown for visual clarity. 
Asterisks indicate statistically significant differences between data sets in the presence of fragment D 




As the mixed micelles comprised four parts of GPSP-ELPC-ELPA for each part of 
the functional component, it was unsurprising to observe the gradual decrease in RH for 
all the mixed micelles in the presence of fragment D (Figure 23C, D). This may be 
suggestive of an unanticipated temperature-sensitive interaction of the outer ELPC block 
with fibrinogen fragment D. Nonetheless, a significant difference in RH was observed 
between the GPRP-ELPB-ELPA and GPSP-ELPB-ELPA mixed micelles, at 37°C and 
below, but not at higher temperatures, a phenomenon we were anticipating in our initial 
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conceptual design. Interestingly, no significant difference in RH was observed for the 
GPRP-ELPC-ELPA and GPSP-ELPC-ELPA mixed micelles at all temperatures tested, 
even though an interaction between the GPRP-ELPC-ELPA mixed micelles and 
fibrinogen was clearly observed for the turbidity assays within this temperature range. 
5.7.  Impact of Mixed Micelles on Fibrin Polymerization 
Early work by Nair et al. suggests that temperature has little effect on the mass-
length ratio of fibrin fibers in thrombin-catalyzed clots within the range of 15°C to 37°C 
[160]. Thus, we do not expect to observe changes in fibrin clot structure within this 
temperature regime. As described previously for the multivalent knob-PEG conjugates, 
fibrin clot formation in the presence of mixed micelles was evaluated using mixture 
turbidity readouts and through confocal imaging of the stabilized network structures. 
5.7.1.  Turbidity Measurements 
The utility of turbidity measurements in the analysis of clot structure has been 
covered extensively in literature and detailed in previous chapters of this document. 
Likewise, we employed turbidity measurements for the evaluation of thrombin 
polymerization dynamics in the presence of the mixed micelles at different temperature 
regimes. As the mixed micelles have a cloud point of 46°C and above, we expect 
minimal interference from turbidity increases arising from ELP aggregation at the 
temperatures tested (22, 32, 42°C). 
As discussed in section 5.6.3, only the turbidities of mixtures with GPRP-ELPB-
ELPA and GPRP-ELPC-ELPA mixed micelles were elevated in the absence of thrombin at 
32°C and 42°C (Figure 24A; compare with Figure 22C). In the presence of thrombin, the 
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turbidity of mixtures in the presence of GPRP-ELPB-ELPA or GPSP-ELPB-ELPA (red 
overbars) actually stayed constant or increased at 42°C while mixtures in the presence of 




Figure 24. Evaluation of clotting parameters of fibrin gels formed in the presence of mixed micelles. 
(A) Mixed micelles (2 µM functional component + 8 µM GPSP-ELPC-ELPA) were preincubated with 
fibrinogen (2 µM) at the indicated temperatures for 1 h. The turbidity readouts of fibrin gels formed 
in the presence (+) or absence (-) of thrombin (0.25 NIHU/mL) following a 1-h incubation at the 
indicated temperatures were reported. (B) Quantitation of protein in the clot liquor through 
absorbance measurements (at 280 nm). Due to the presence of a single tryptophan residue in each 
ELP chain, the absorbance from soluble ELP was expected to be minimal. Thus, the measured 




Analysis of the clot liquor suggests that the amount of unclotted protein was 
similar, regardless of the identity of the mixed micelle present (Figure 24B). This 
suggests that the clottability of the fibrin gels formed (or not formed in the absence of 
thrombin) was not affected by the mixed micelles. Taken together, these results are 
suggestive of a structural reorganization of the fibrin matrix in the presence of the mixed 
micelles at 32°C and 42°C, not unlike the situation we encountered in the previous 
chapter (refer to section 4.4). 
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5.7.2.  Confocal Imaging 
We proceeded to evaluate clot structure through confocal microscopy as described 
previously. Regardless of the type of imaging method, we are unable to control the 
temperature at which the clots are imaged. However, from past experience with confocal 
imaging (section 4.6), we found that the fibrin clot structures formed following a 1-h 
room temperature incubation with thrombin were stable for several days. Thus, we 
assumed that the fibrin clot structures formed following a 1-h incubation with thrombin at 
the desired temperatures would be similarly stable. 
As expected, the fibrin clots formed in the presence of the ELP diblock proteins at 
22°C were largely similar (Figure 25). At this temperature (< Tt1), we expect the ELP 
diblock proteins to exist as monomers. At an equimolar GPRP:fibrinogen ratio, the 
impact on fibrin polymerization dynamics should be minimal (refer also to 4.4.1). At 
32°C, we observe thinner fibers and large clusters of fibrinogen/fibrin in the presence of 
GPRP-ELPB-ELPA and GPRP-ELPC-ELPA mixed micelles. Using labeled ELP diblock 
proteins, these clusters were shown to comprise both fibrinogen and the ELP diblocks 
(data not shown). At 42°C, the clusters were smaller and the surrounding fibrin fibers 






Figure 25. Confocal images of fibrin gels formed in the presence of mixed micelles. Images were 
rendered from 35 ×  35 ×  10 µm slices. The hydrogels were formed within sealed chambers on glass 
slides and imaged using laser scanning confocal microscopy. Control clots (shown in the first column) 
were formed at the indicated temperatures using 3 µM fibrinogen and 0.25 NIHU/mL thrombin. 15 





5.8.  Discussions and Conclusions 
Many stimuli-responsive systems reported in literature involve temperature- or 
pH-induced collapse or swelling of selective layers of two- or three-dimensional 
assemblies. In contrast, this work looks at the selective collapse of a polymer block 
within a selected layer of a three-dimensional assembly. The differential collapse of 
polymer blocks amongst non-collapsing polymer blocks poses unique challenges but is of 
significant value for the future development of multi-responsive 3-D assemblies that 
maintain structural integrity while displaying different ligands in response to 
environmental conditions. 
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Given the extensive literature on ELPs and their transitioning characteristics, the 
use of ELPs is particularly advantageous to the design of such self-assembling stimuli-
responsive display systems. In addition, the ability to synthesize biopolymers with 
specific sequence compositions and functional handles facilitates the rapid 
characterization and study of the mixed assemblies formed using high throughput assays 
such as SYPRO Orange and ELISA. The defined compositions and molecular weights of 
the ELP diblock proteins used in this work also facilitated the formation of stable 
nanometer sized micelles with low polydispersities, allowing us to discern subtle changes 
in RH due to the binding of fibrinogen fragment D to the peptide-displaying micelle. 
The solid- and solution-phase affinity assays together with the DLS data suggest 
temperature-modulated avidities of the mixed micelles towards fibrinogen at different 
temperature regimes, likely due to the display of GPRP at lower temperatures, and 
retraction of GPRP at elevated temperatures, thus validating our starting hypothesis. 
Evaluation of fibrin clot structures formed within the different temperature regimes also 
suggest that clot structure was most severely perturbed at 32°C, where we expect GPRP 
display, and returns to the control morphology at 42°C, where we expect GPRP 
retraction. 
However, it is noted with interest that we did not achieve a clean switch in avidity 
from a fibrinogen-binding mixed micelle to a non-binding mixed micelle in all the assays 
presented. This may suggest interference of ELPB block collapse by the neighboring 
ELPC blocks in the mixed micelle. Notably, DLS particle intensity readouts of mixed 
micelles in the absence of fibrinogen fragment D did not register noticeable changes at 
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the expected Tt,B (data not shown), which would have been a useful indicator of changes 
in the micellar shell as the ELPB blocks collapsed.  
Alternatively, the 1:4 molar ratio of GPRP-ELPB-ELPA-to-GPSP-ELPC-ELPA 
used may not be optimized to dislodge fibrinogen from the collapsed GPRP-ELPB-ELPA 
diblock protein. In particular, it is noted that fibrinogen fragment D was not released from 
GPRP-ELPB-ELPA-only micelles during the temperature ramp (Figure 23A), as expected 
from ELISA results suggesting that knob:hole interactions are not disrupted at elevated 
temperatures (Figure 20). The presence of an adequate proportion of GPSP-ELPC-ELPA 
is therefore critical not only for maintaining micelle structural integrity past Tt,B, but also 




RECOMMENDATIONS AND FUTURE OUTLOOK 
 
As the field of regenerative medicine continues to grow, we are seeing a 
concomitant explosion in the varieties of biomaterials being produced, characterized and 
tested in laboratories all around the world. This natural association is a result of the need 
to culture cells outside the body in suitable media to support their growth and 
development, or even more fundamentally, to understand how cells respond to such 
materials in order to facilitate the development of the next generation of novel 
biomaterials. In many instances, cells are known to “reorganize” the surrounding matrix 
to support their proliferation and/or differentiation. In that sense, biomaterials are not 
meant to be permanent structures but should simply be engineered to facilitate the 
process of growth and repair. Fibrin is the ultimate example of such a provisional matrix, 
being our natural first line of defense against tissue and vascular injury. Thus, fibrin is 
used in the clinic, as a surgical hemostat and sealant, and also in the laboratory, as a 
biomaterial. 
Nonetheless, the formation of the fibrin matrix from its soluble precursor entails 
the addition of enzymes, creating handling issues both in the operating theater and on the 
bench. Thus, our goal was to develop a temperature-triggered polymerizing gel through 
the use of an adjunct that alters fibrin polymerization dynamics differentially as a 
function of mixture temperature. As fibrin polymerization is primarily a process of self-
assembly mediated by knob:hole interactions, we were interested in evaluating the extent 
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to which we could perturb this process and to determine if we could exploit it to our 
advantage.  
6.1.  Recommendations from Dissertation Work 
In Chapter 3, we were primarily interested in evaluating the stability of knob:hole 
interactions, particularly in the presence of other competing fibrin knobs. From Figure 3, 
we note that knob ‘A’ mimic GPRP was much more effective at competing off the bound 
fibrinogen from immobilized GPRP-FNIII9-10 as compared to the native knob ‘A’ 
sequence GPRV. Disappointingly, in the presence of native knobs presented in the 
context of a fibrin matrix, GPRP-FNIII9-10 was not significantly retained within matrices 
over longer time periods (Figure 5). Nonetheless, it is noted that under perfusion, GPRP-
FNIII9-10 was indeed retained to a much larger extent compared to the non-binding 
control (work contributed by Brown and Stabenfeldt [135]). This finding seems to 
suggest that the A:a interactions are indeed more resistant to rupture under shear 
compared to rupture by thermal dissociation, as proposed by Averett et al. [161] 
In Chapter 4, we employed the use of GPRPn-PEG conjugates to evaluate the 
capacity of such multivalent structures for reorganizing the native fibrin matrix structure. 
In contrast to the somewhat lackluster performance of monovalent GPRP-FNIII9-10 
within fibrin matrices, the GPRPn-PEG conjugates mediated a wide dynamic range of 
fibrin network morphologies at a 1:1 conjugate:fibrinogen ratio (Figure 12). Notably, this 
finding concurs with the larger conjugate:fibrinogen ratios required to perturb matrix 
structure in the case of monovalent GPRP-PEG conjugates of a similar size range [162]. 
In other words, it appears to be more feasible to manipulate fibrin hydrogel properties 
through the use of artificial physical crosslinkers, rather than attempting to completely 
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halt the process of fibril assembly through the addition of monovalent GPRP-displaying 
peptides or conjugates. Thus we may envision the use of long mobile PEG linkers (such 
as our 20 kDa GPRP4-PEG) to drive the formation of a loose weak gel, and the use of 
smaller pincer-type PEG linkers to drive the formation of a tighter stronger gel. In other 
words, we may be able to create a fibrin hydrogel with temperature-responsive properties 
through the use of a conjugate that exhibits temperature-responsive structural changes. In 
view of the likelihood that knob:hole interactions are exceptionally resistant to shear 
forces, we would expect the conjugate to remain engaged with fibrinogen/fibrin as it 
undergoes these structural changes. 
In Chapter 5, we embarked on the development of a self-assembling system that 
exhibits temperature-modulated avidities towards fibrinogen. Due to the problems 
encountered in Chapter 4 regarding the limited characterization techniques available for 
synthetic conjugates, ELPs were used in this proof-of-principle design. Moreover, ELP 
diblock proteins may form stable micellar nanostructures [121], offering a convenient 
means of creating knob-displaying multivalent structures that could perturb fibrin 
network structure. Thus we found that such self-assembling GPRP-displaying mixed 
micelles exhibit temperature-modulated avidities for fibrinogen (Figure 22) and exerted 
variable reorganization capacities on fibrin (Figure 25). However, upon a temperature 
ramp, it appeared that the disengagement of fibrinogen from the mixed micelles was 
slower than anticipated (Figure 23). Again, this may be a result of the resistance of the 
knob:hole interaction towards physical rupture, or it could suggest that we should have 
used a weaker binder with a higher off-rate, such as GPRV [163]. Indeed, an ideal knob 
peptide sequence for this application would be one that exhibits a high affinity for 
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fibrin(ogen) holes at ambient temperatures but a reduced affinity at elevated 
temperatures. Other process parameters that could be optimized include the ratio of the 
functional-to-nonfunctional component (currently at 1:4) and the relative lengths of the 
outer ELP block (now at 80 repeats for ELPB versus 40 repeats for ELPC). 
Summarizing, this dissertation explored several different methods of modulating 
fibrin matrix structure via knob:hole interactions. Significantly, we found that fibrin 
matrix structure can be controlled through the simple addition of multivalent knob-
displaying conjugates that act as crosslinkers of fibrinogen. This suggests that stimuli-
responsive fibrin mixtures can be engineered through the use of stimuli-responsive 
crosslinkers without having to modify the fibrin molecule itself. 
6.2.  Broader Implications 
We started this project with the straightforward goal of creating a fibrin-based 
mixture that is fluid (i.e. predominantly viscous) at ambient temperatures but solid (i.e. 
predominantly elastic) at physiological temperatures through the use of a temperature-
responsive adjunct. Many of the challenges we encountered in the process arose from 
inherent properties of fibrin molecule itself, as well as our choice of the temperature-
responsive component. 
6.2.1.  Mechanical Aspects of Fibrin as a Scaffold 
Unlike the case for most synthetic polymer hydrogels, protein hydrogel networks 
formed both in vitro and in vivo typically comprise protein chains that are assembled into 
fiber bundles. Fibrin monomer assembly involves the formation of double-stranded fibrin 
protofibrils that assemble laterally to form fibrils that can aggregate to form even larger 
fibers. In general, lateral aggregation and branching act in opposition to each other such 
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that coarse/turbid clots comprise thick fibers with few branch points whereas fine/clear 
clots comprise thin fibers with many branch points. Since fiber thickness and branchpoint 
density both contribute to clot rigidity, the balance between both factors effects a 
maximal elastic modulus for clots formed using a fixed amount of fibrinogen [47]. 
In addition, early permeation experiments suggested that the pore structure in 
coarse and fine clots were remarkably similar [164], implying some kind of inbuilt 
mechanism in the fibrin assembly scheme that regulates matrix mechanical properties. 
The ability to perturb this mechanism through the addition of a non-native crosslinking 
component, like those studied in this dissertation, is a powerful tool to study the 
relationship between fibrin assembly and matrix properties. The results from such studies 
may then be used to shed light on the assembly and formation of protein-based hydrogels 
using biologically derived proteins such as collagen or gelatin, or recombinantly 
engineered proteins such as the ELP triblock proteins discussed in section 2.3.3. 
Significantly, this knowledge would offer a rational means of strengthening such 
hydrogels without resorting to general covalent crosslinkers like glutaraldehyde or 
genipin. 
Fibrin matrices also exhibit a characteristic strain stiffening behavior common to 
many protein polymer networks. Using molecular theory, Storm et al. suggested that this 
nonlinear elastic response is inherent to networks comprising semiflexible filaments with 
comparable persistence length (lp) and contour length (Lc) [165]. In the case of fibrin, lp is 
about 0.5 µm and Lc ranges from 0.1 to 0.4 µm, depending on the network mesh size 
[165]. This is in contrast with many synthetic hydrogel networks comprising flexible 
filaments where lp << Lc. The phenomenon of strain hardening is also related to the 
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unusual negative normal stresses exhibited by such networks in response to sinusoidal 
shear strains in the rheometer [166]. This physiologically significant though less well-
studied feature allows for the compression and syneresis of fibrin clots under high shear 
stress, such as in blood vessels [167].  
Fibrin matrices demonstrate some of the largest degrees of strain hardening – the 
shear modulus of fibrin at 50% strain can be as much as 20 times that at low strains (< 
10%) [168]. Interestingly, the incorporation and activation of platelets in fibrin networks 
eliminates this strain hardening behavior and increases the shear modulus at low strains 
to meet the maximal elastic modulus obtained from the equivalent fibrin-only networks at 
higher strains [168]. This suggests that we may tune the elastic modulus of fibrin 
matrices at low strains (typically < 10%) by 20-fold through the facile addition of a 
contractile component, such as GPRP-ELPB-ELPA micelles (from Chapter 5), that 
interacts with fibrin. It would be interesting to see how cells respond to such “pre-
strained” stiff matrices since we would expect the strained fibers to also partially unfold 
[169, 170], potentially affecting the presentation of protein- and cell-binding sites on the 
fibers. Since extracellular matrix proteins (such as fibronectin, collagen) are generally 
under strain in native matrices, such studies can be used to understand cellular responses 
to strained and unstrained matrices, particularly in a three-dimensional hydrogel. 
A final intriguing possibility arises from observing clusters of fibrinogen/fibrin 
scattered amidst the networks formed in the presence of multivalent conjugates (Figure 
12 and 25). Since we were expecting to observe homogeneous fibril networks, the 
formation of these clusters may reflect topological constraints in fibril organization. 
However, the ability to create concentrated nodules of proteins may be an advantage by 
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allowing us to create local increases in crosslink density that increase the bulk modulus 
while preserving the average mesh size, akin to the system reported by Browning et al. 
[171]. Under the current experimental conditions, fibrinogen/fibrin cluster formation was 
associated with the formation of thinner fibrils. This could explain why we did not 
observe dramatic changes in the mechanical properties of such matrices (Figure 13) even 
though the clot structures were so different. For this dissertation, we focused on the use 
of conjugates near an equimolar knob:hole ratio in a dilute fibrinogen solution (~1 
mg/mL) at moderate thrombin concentrations (~0.25 NIH U/mL). Changing these 
parameters could permit the formation of thick fibers with interspersed clusters of 
fibrinogen/fibrin that could potentially increase the strength of fibrin gels.  
6.2.2.  ELPs as Structural Actuators 
Many comparisons in literature have been made between ELPs and the synthetic 
polymer equivalent, PNIPAM. In particular, the bulk transition temperature of ELPs 
exhibits a very strong concentration dependence, which has been attributed to the 
inherent stiffness of the peptide backbone [102]. However, it would seem that the 
transition of an ELP as a molecular actuator, inducing some kind of change in response to 
some kind of stimulus such as the system proposed in Chapter 5, should be dependent on 
chain transition temperature, rather than the bulk transition temperature.  
In the few studies reported that use ELPs as actuators (discussed in section 2.3.5) 
rather than molecular aggregators, it seems that the transition temperatures were higher 
than what we would expect, based off the hydrophobicity scale proposed by Urry [96]. 
This could be because of the dependency of the transition temperature on ELP chain 
length, or the effect of the adjacent protein sequences on the transition temperature of the 
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ELP sequence. In the system described in Chapter 5, we used an ELP chain that was 
much longer than those described in previous studies, thus circumventing the 
controversies surrounding the behavior of short ELPs (typically < 5 repeats) in 
comparison to their longer counterparts. However, we also introduced a topological 
requirement since the transitioning ELPB blocks had to collapse amidst the more 
abundant non-transitioning ELPC block. This subtle change proved difficult to probe 
under our current experimental settings but is a valuable prelude for the design of single-
layer multi-responsive surfaces.  
Many of the multi-responsive systems reported in current literature are multi-layer 
constructs, with each layer responding to a different stimulus. However, such a strategy 
would not be sustainable for the design of systems that have to respond to more than 
three different stimuli due to transportation issues across the layers. The ideal system 
would therefore present all the responsive blocks within the same layer, allowing them 
equal access to the surroundings. However, this assumes that we are able to achieve 
independent collapse of individual blocks among the surrounding blocks, a fundamental 
mechanistic requirement that was out of scope for the present study. 
Two major competing models have been proposed to explain the contractility of 
elastin – the Tamburro and the Urry model [172]. While the Urry model describes the 
formation of structured β-spirals from consensus VPGXG sequences (described in 
section 2.3.1), the Tamburro model theorizes the formation of dynamic quasi-folded and 
semi-extended distorted β structures from consensus XGGYG sequences. While most 
publications agree that the formation of β-turns plays a fundamental in the protein 
elasticity, recent molecular simulations and experimental observations seem to suggest 
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that the ELP structure above the transition temperature is much more dynamic and 
disordered than previously thought [97, 126]. This could have implications on the use of 
ELPs in the design of molecular actuators such as that proposed in this dissertation. 
6.3.  Conclusions 
Given the decades of study on protein structure and recombinant protein 
production, the time is now ripe for the application of this knowledge in the custom 
engineering of protein-based biomaterials for use in tissue engineering and regenerative 
medicine. While we have chosen to work with fibrinogen as our scaffold protein in this 
dissertation, the knowledge gained can be used to outline some basic principles in 
controlling protein matrix properties since most ECM proteins are similarly fibrillar in 
nature. The addition of a stimulus-responsive component to our scaffold design also 
offered a further dimension of control over matrix assembly and morphology in response 
to an external stimulus, such as temperature.  
In conclusion, this dissertation probes some of the fundamental properties of 
polymerizing or self-assembling proteins for the engineering of matrices with potential 
applications going far beyond that of basic hemostats or sealants. 
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APPENDIX A 
EVALUATION OF MULTIVALENT GPRP CONJUGATES 
 
GPRP-derived mimics are known to inhibit fibrin assembly while two-headed 
GPRP linkers have been found to promote FXIIIa activity through fibrinogen assembly 
[42, 139]. However, if the distance of the linker region were smaller than the minimum 
distance between abutting holes ‘a’ of two fibrin(ogen) molecules, the expectation is that 
the bivalent GPRP conjugate should behave as an inhibitor of fibrin assembly, albeit with 
increased avidity. Everse et al. found that the distance between the terminal glycines of 
two bound knobs in abutting holes ‘a’ was 32 Å [18], corresponding closely to the 
solution length of the 900 Da PEG linker used by Lorand et al. [42]. Thus, we 
hypothesize that the conjugation of GPRPAAC to bis(maleimido)ethane, with a spacer 
arm length of only 8 Å, would result in the formation of a two-headed ligand that does 
not span the required 32 Å. This bivalent conjugate, denoted as GPRP2-M, should 
therefore inhibit fibrin polymerization, possibly to a greater extent as compared to the 
GPRP peptide alone. As a control, we also created a monovalent conjugate using N-
ethylmaleimide, denoted as GPRP-M, to show that the conjugation process had no 
adverse effect on peptide efficacy. 
A.1.  Materials and Methods 
GPxP2-M and GPxP-M were prepared in the same manner as the PEG conjugates 
used in chapter 4 (see section 4.2.1 for details). GPRPAAC and GPSPAAC peptides were 
sourced from Genscript, bis(maleimido)ethane from Thermo Scientific, N-
ethylmaleimide from Alfa Aesar. However, due to the small sizes of both the peptides 
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and the maleimide-containing moieties that precludes dialysis as a separation method, we 
employed equimolar sulhydryl-to-maleimide reaction ratios during the conjugation and 
did not attempt to purify the product. 
Turbidity measurements and analyses of the % clottable protein were conducted 
as described in section 4.2.2. 
A.2.  Results and Discussion 
As expected, the non-binding peptide GPSP has no significant impact on fibrin 
polymerization (Figure 26A), while GPRP reduced mixture turbidity in a dose-dependent 
manner (Figure 26B). The turbidity profiles in the presence of a 100:1 knob:fibrinogen 
molar ratio for GPSP-M and GPSP2-M suggests a perturbation of fibrin clot structure at 
these concentrations (Figure 26C, E). This is likely to be a result of the trace amounts of 
dimethyl sulfoxide (DMSO) required to dissolve the reagents used in the conjugation 
reaction. Disregarding the spurious results at the 100:1 knob:fibrinogen dosage for 
GPRP-M and GPRP2-M, we note that GPRP-M seems to behave similarly to GPRP, 
suggesting that the conjugation process itself has no significant impact on peptide 
function (Figure 26B, D). As expected, GPRP2-M appears to have a greater impact on the 




Figure 26. Representative turbidity profiles in the presence of peptides and peptide conjugates at the 
indicated knob:fibrinogen molar ratios. Data presented for GPSP (A), GPRP (B), GPSP-M (C), 
GPRP-M (D), GPSP2-M (E), GPRP2-M (F). 
 
 
Next, we evaluated the amount of unclotted protein remaining in the clot liquor 
retrieved from these clots. The results suggest that the bivalent GPRP2-M conjugates 
were indeed more efficient at inhibiting fibrin polymerization compared to the 
monovalent GPRP-M conjugates or the control GPRP peptide (Figure 27), thus 
supporting our hypothesis.  
 115 
 





EFFECT OF FIBRINOGEN ON ELP TRANSITION 
TEMPERATURES 
 
The transition characteristics of ELPs are affected by changes in the surface 
hydrophobicity of their fusion partner [101, 131]. Thus, one of the concerns in our design 
of the knob-displaying mixed micelle system is the effect of fibrinogen binding on the 
transition characteristics of the ELP diblock proteins. Due to the large size of fibrinogen 
(~340 kDa) in comparison to the ELP diblock protein (~50 kDa), it is possible that the 
binding of soluble fibrinogen to the GPRP-displaying protein would increase its 
transition temperatures (Tt1 and Tt2). Here, we were interested in evaluating the transition 
temperatures of the ELP diblock proteins in the presence of fibrinogen and fibrinogen 
fragment D. The choice of fragment D as a second control was based upon its smaller 
size (~88 kDa) and the fact that it comprises only a single set of holes (see Figure 1A), 
thus eliminating potential confounding effects arising from network formation (see also 
section 5.6.3).  
B.1.  Materials and Methods 
The SYPRO Orange assay was carried out as described in section 5.2.5. The 
experiments were conducted using a standard concentration of 10 µM ELP mixtures 
(comprising 2 µM of the indicated “functional component” and 8 µM of GPSP-ELPC-
ELPA) and 2 µM of fibrinogen or fragment D. 
B.2.  Results and Discussion 
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SYPRO Orange is one of several different protein-binding fluorescent dyes used 
for the evaluation of protein stability and/or protein aggregation [159]. Thus, we expected 
to observe an increase in the SYPRO Orange fluorescent signal beginning at about 45°C 
in the presence of fibrinogen and fragment D, corresponding to protein denaturation 
(Figure 28A). In Figure 28B, we note that Tt1 was not affected by the presence of 
fibrinogen nor fragment D, suggesting that micelle formation was not adversely affected 
(see also sections 5.4.1 and 5.5.1.). However, the presence of fibrinogen led to an 
increase in the error associated with the evaluation of Tt2 due to the background signal 
arising from the denaturing protein. Nonetheless, it would appear from these results that 
the presence of fibrinogen and fragment D did not substantially change the transition 




Figure 28. Temperature transition characteristics of ELP diblock proteins in the presence of 
fibrinogen evaluated using SYPRO Orange. (A) Representative fluorescent readouts from 2 µM 
fibrinogen and 2 µM fibrinogen fragment D, compared against the buffer blank. (B) Transition 
temperatures of 10 µM 1:4 functional:GPSP-ELPC-ELPA mixtures in the presence of fibrinogen and 
fragment D. Closed symbols correspond to Tt1 and open symbols correspond to Tt2. Data reported as 




QUANTIFICATION OF FIBRIN NETWORK STRUCTURE USING 
IMAGEJ 
 
Parameters that can be used to quantify network morphology include fiber 
diameter, fiber density and branchpoint density. Such quantifications of fibrin network 
structures have been made using scanning electron micrographs and reflection laser 
scanning micrographs [47, 150]. For this project, the fibrin networks were visualized 
using fluorescently-labeled fibrinogen under confocal laser scanning microscopy, making 
it challenging to discern between true branchpoints and fibers that have simply crossed 
over at different depths. Nonetheless, we should be able to obtain a measure of the 
relative fiber diameters across the different networks observed (Figures 12 and 25). With 
this goal in mind, Peter J. Yang contributed a macro script that could be run using the 
NIH image processing software, ImageJ. Briefly, the script converted the 3D networks 
rendered using the Carl Zeiss ZEN 2008 LE software, into binary images, which were 
then skeletonized. The ratio of the pixels from the binary images to the pixels from the 
skeletonized images (thresholded-over-skeletonized) should then provide a relative 
estimate of fiber diameter. 
C.1.  Materials and Methods 
As proof of principle, the confocal images obtained from the multivalent PEG 
conjugate project (refer to section 4.2.5 for the image acquisition technique) were used in 




Figure 29. Main processing function for calculating relative fiber diameters on confocal images of 







C.2.  Results and Discussion 
From a representative image of a fibrin clot formed in the presence of an 
equimolar concentration of the 5 kDa GPRP2-PEG conjugate, clusters of fibrinogen/fibrin 
can be observed (Figure 30A; compare with Figure 12). These aggregates were found to 
cause problems during the skeletonization of the binary image since an irregular cluster is 
clearly not a fiber (Figures 30B, C). To overcome this problem, sections of the 
micrograph with such aggregates were cropped out (Figure 30D), converted into binary 
(Figure 30E), then skeletonized (Figure 30F). The resulting skeletonized network 
appeared to be more representative of the actual fiber network structure. 
The results obtained from the analysis of “unprocessed” micrographs without the 
aggregates removed are shown in Figure 30G. It can be seen that the presence of these 
aggregates had artificially increased the thresholded-over-skeletonized ratio for GPRP2-
PEG conjugates larger than 2 kDa in size. However, it can also be seen that the 
thresholded-over-skeletonized ratio is comparable across all the GPSP2-PEG controls, as 
well as the no conjugate control (data not shown), indicating that the script does work as 
a matter of principle, as long as a homogeneous fiber network is present. 
The results from the analysis performed on “processed” micrographs with existing 
aggregates manually cropped out are shown in Figure 30H. These results suggest that that 
the thresholded-over-skeletonized ratios in the presence of the GPRP2-PEG conjugates 
were reduced, which is what we would expect from our observation of thinner fibers in 
these clots.  
However, several drawbacks to this method are noted. First, the thresholded-over-
skeletonized ratios of the control clots were already quite low to begin with (~2.8) and 
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since this methodology has a lower boundary of 1.0 (i.e. a fiber with 1 unit diameter), it 
would be difficult for us to observe any stark differences using these values. In addition, 
the tenuous fibrin networks formed in the presence of the larger conjugates such as the 
7.5 kDa GPRP2-PEG, 10 kDa and 20 kDa GPRP4-PEG conjugates were near the lower 
threshold limit of the images and did not render well following the masking and 
skeletonizing procedure. In other words, the script did not yield any results from several 
of these images since there was no visible network seen after thresholding. Nonetheless, 
this script provides a useful starting point for acquiring numerical data from a large 
number of raw images, allowing us to make quantitative and statistical comparisons 




Figure 30. Quantification of fibrin networks formed in the presence of GPRP2-PEG and GPSP2-PEG 
conjugates. (A) Representative confocal image of a clot (1 mg/mL fibrinogen, 0.25 NIH U/mL 
thrombin, 5 Loewy units/mL factor XIIIa) formed in the presence of an equimolar concentration of 5 
kDa GPRP2-PEG. Image was rendered from a 89×89×10 µm slice (i.e. Z-stack of the complete field of 
view under the 100×  objective). (B) Appearance of the thresholded image after conversion to 8-bit 
grayscale, smoothing, then conversion to binary. (C) Appearance of the skeletonized image after 
skeletonizing. (D-F) Same procedure carried out on the processed image with the aggregates 
manually cropped out. (G) Thresholded-to-skeletonized ratio from the analysis of unprocessed 
images containing aggregates. (H) Thresholded-to-skeletonized ratio from the analysis of processed 
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